(dp1
S'10.1016/j.ijid.2006.09.010'
p2
(lp3
S'nasal vaccine candidate'
p4
aS'nasal vaccine'
p5
aS'healthy adults'
p6
aS'adverse events were'
p7
aS'7 15 30'
p8
aS'30 and 60'
p9
aS'0 7 15'
p10
aS'Adverse events were'
p11
aS'nasal'
p12
aS'trial'
p13
aS'HBsAg and HBcAg'
p14
aS'hepatitis B virus'
p15
aS'data collection sheets'
p16
aS'placebo group'
p17
aS'anti HBc antibodies'
p18
aS'30 days after'
p19
aS'anti HBs antibody'
p20
asS'10.1016/0163-7258(88)90016-2'
p21
(lp22
S'temperature regulation'
p23
aS'evidence'
p24
aS'system theoretical'
p25
aS'temperature regulation adaptation'
p26
aS'adaptation'
p27
aS'regulation adaptation'
p28
aS'Complementary system theoretical'
p29
aS'temperature'
p30
aS'Complementary'
p31
aS'system'
p32
aS'regulation'
p33
aS'fever Complementary'
p34
aS'theoretical'
p35
aS'fever'
p36
aS'experimental evidence'
p37
aS'mechanisms'
p38
aS'adaptation and fever'
p39
asS'10.1016/j.jada.2006.08.007'
p40
(lp41
S'gestational weight gain'
p42
aS'excessive gestational weight'
p43
aS'prenatal nutrition interventions'
p44
aS'inadequate and excessive'
p45
aS'Social Cognitive Theory'
p46
aS'excessive gestational'
p47
aS'education and counseling'
p48
aS'appropriate gestational weight'
p49
aS'Institute of Medicine'
p50
aS'both inadequate'
p51
aS'among pregnant adolescents'
p52
aS'nutrition education'
p53
aS'uoi B758G 4M9NHJD'
p54
aS'prenatal nutrition'
p55
aS'among pregnant teens'
p56
aS'effect on birth'
p57
aS'highest risk'
p58
asS'10.1016/j.clinthera.2006.05.008'
p59
(lp60
S'6 month'
p61
aS'blind placebo controlled'
p62
aS'randomized double blind'
p63
aS'month randomized double'
p64
aS'double blind placebo'
p65
aS'6 month randomized'
p66
aS'sibutramine in obese'
p67
aS'sibutramine'
p68
aS'sibutramine group'
p69
aS'group at end'
p70
aS'placebo group'
p71
aS'obese Mexican adolescents'
p72
aS'placebo'
p73
aS'diet and exercise'
p74
aS'05 for all'
p75
aS'sibutramine group changed'
p76
aS'2 95 CI'
p77
asS'd'
(lp78
S'nasal vaccine candidate'
p79
aS'nasal vaccine'
p80
aS'healthy adults'
p81
aS'adverse events were'
p82
aS'7 15 30'
p83
aS'30 and 60'
p84
aS'0 7 15'
p85
aS'Adverse events were'
p86
aS'nasal'
p87
aS'trial'
p88
aS'HBsAg and HBcAg'
p89
aS'hepatitis B virus'
p90
aS'data collection sheets'
p91
aS'placebo group'
p92
aS'anti HBc antibodies'
p93
aS'30 days after'
p94
aS'anti HBs antibody'
p95
aS'50 g HBcAg'
p96
aS'50 g HBsAg'
p97
aS'Source data collection'
p98
aS'healthy'
p99
aS'day 30'
p100
aS'trial in healthy'
p101
aS'core antigens'
p102
aS'seroconversion in 100'
p103
aS'proportion of subjects'
p104
aS'vaccine'
p105
aS'HBsAg HBcAg vaccine'
p106
aS'HBcAg vaccine candidate'
p107
aS'60 days'
p108
aS'day 90 75'
p109
aS'HBs and anti'
p110
aS'9 8 palate'
p111
aS'9 8 headache'
p112
aS'34 1 rhinorrhea'
p113
aS'included sneezing 34'
p114
aS'8 palate itching'
p115
aS'2 nasal stuffiness'
p116
aS'12 2 nasal'
p117
aS'1 rhinorrhea 12'
p118
aS'mild in intensity'
p119
aS'events were recorded'
p120
aS'were recorded during'
p121
aS'anti HBc'
p122
aS'study'
p123
aS'anti HBc seroconversion'
p124
aS'well tolerated'
p125
aS'nasal route'
p126
aS'12h 24h 48h'
p127
aS'24h 48h 72h'
p128
aS'6h 12h 24h'
p129
aS'events were actively'
p130
aS'were actively recorded'
p131
aS'via nasal spray'
p132
aS'hepatitis B vaccine'
p133
aS'19 healthy male'
p134
aS'were randomly allocated'
p135
aS'systemic adverse events'
p136
aS'healthy male adults'
p137
aS'physiologic saline solution'
p138
aS'day 90'
p139
aS'CIGB Havana Cuba'
p140
aS'nasal co administration'
p141
aS'immunization schedule'
p142
aS'placebo'
p143
aS'HBs antibody levels'
p144
aS'Source data'
p145
aS'first'
p146
aS'B virus HBV'
p147
aS'safety and immunogenicity'
p148
aS'events were defined'
p149
aS'local adverse events'
p150
aS'events were reported'
p151
aS'clinical trial'
p152
aS'50'
p153
aS'responders anti HBs'
p154
aS'total'
p155
aS'day'
p156
aS'HBsAg HBcAg'
p157
aS'hepatitis B vaccines'
p158
aS'Center for Genetic'
p159
aS'Genetic Engineering Biotechnology'
p160
aS'strong immunogenicity'
p161
aS'clinical'
p162
aS'HBcAg and HBsAg'
p163
aS'45 years'
p164
aS'immunogenicity of HBcAg'
p165
aS'HBcAg'
p166
aS'route with 50'
p167
aS'g HBsAg following'
p168
aS'linked to 50'
p169
aS'HBcAg HBsAg vaccine'
p170
aS'response to HBcAg'
p171
aS'HBsAg vaccine candidate'
p172
aS'HBcAg non covalently'
p173
aS'candidate in healthy'
p174
aS'healthy volunteers immunized'
p175
aS'phase'
p176
aS'Center for Toxicology'
p177
aS'J Finlay Hospital'
p178
aS'Carlos J Finlay'
p179
aS'doses per study'
p180
aS'Frequency of each'
p181
aS'number of applied'
p182
aS'applied doses per'
p183
aS'per study group'
p184
aS'event with respect'
p185
aS'type of adverse'
p186
aS'well'
p187
aS'60'
p188
aS'severe'
p189
aS'vaccine candidate'
p190
aS'hepatitis'
p191
aS'vaccine recipients'
p192
aS'chronic'
p193
aS'nasal wash'
p194
aS'0 5ml'
p195
aS'chronic HBV infected'
p196
aS'19 healthy'
p197
aS'any'
p198
aS'World Health Organization'
p199
aS'results'
p200
aS'nasal co'
p201
aS'HBsAg'
p202
aS'subjects'
p203
aS'systemic adverse'
p204
aS'any other'
p205
aS'written informed consent'
p206
aS'immunization'
p207
aS'mice'
p208
aS'chronic infection'
p209
aS'adverse event'
p210
aS'other'
p211
aS'two'
p212
aS'vaccine group'
p213
aS'anti HBs'
p214
aS'Genetic Engineering'
p215
aS'chronic HBV'
p216
aS'volunteers'
p217
aS'immunogenic'
p218
aS'mixture of 50'
p219
aS'axillary temperature'
p220
aS'core'
p221
aS'immunity'
p222
aS'more than'
p223
aS'general malaise'
p224
aS'30 days'
p225
aS'systemic'
p226
aS'100'
p227
aS'systemic immunity'
p228
aS'anti'
p229
aS'each'
p230
aS'local adverse'
p231
aS'animal'
p232
aS'full length'
p233
aS'knowledge'
p234
aS'anti HBs titers'
p235
aS'events were mild'
p236
aS'safe'
p237
aS'applied doses'
p238
aS'placebo group withdrew'
p239
aS'study group'
p240
aS'virus'
p241
aS'patients with chronic'
p242
aS'intensity'
p243
aS'candidate comprising HBV'
p244
aS'study in healthy'
p245
aS'demonstration of safety'
p246
aS'safe well tolerated'
p247
aS'comprising HBV antigens'
p248
aS'tolerated and immunogenic'
p249
aS'vaccine candidate comprising'
p250
aS'unexpected events were'
p251
aS'using corresponding ELISA'
p252
aS'vaccine elicited anti'
p253
aS'tolerated Adverse reactions'
p254
aS'seroprotective anti HBs'
p255
aS'well tolerated Adverse'
p256
aS'dose Anti HBs'
p257
aS'elicited anti HBc'
p258
aS'each dose Anti'
p259
aS'after each dose'
p260
aS'titers were evaluated'
p261
aS'severe or unexpected'
p262
aS'reactions included sneezing'
p263
aS'per nostril Adverse'
p264
aS'early as day'
p265
aS'kits at days'
p266
aS'1h 6h 12h'
p267
aS'anti HBc titers'
p268
aS'recorded 1h 6h'
p269
aS'immunization schedule while'
p270
aS'100 of subjects'
p271
aS'were evaluated using'
p272
aS'nostril Adverse events'
p273
aS'actively recorded 1h'
p274
aS'evaluated using corresponding'
p275
aS'intensity No severe'
p276
aS'corresponding ELISA kits'
p277
aS'HBs titer 10IU'
p278
aS'days and 30'
p279
aS'days after each'
p280
aS'HBc titers were'
p281
aS'safe and well'
p282
aS'75 All subjects'
p283
aS'subjects as early'
p284
aS'placebo group remained'
p285
aS'30 and 90'
p286
aS'72h 7 days'
p287
aS'90 75 All'
p288
aS'8 and general'
p289
aS'group remained seronegative'
p290
aS'remained seronegative during'
p291
aS'maximum at day'
p292
aS'anti HBs titer'
p293
aS'limiting and mild'
p294
aS'reactions were all'
p295
aS'were all self'
p296
aS'all self limiting'
p297
aS'Adverse reactions included'
p298
aS'placebo via nasal'
p299
aS'five dose schedule'
p300
aS'administered in two'
p301
aS'0 9 physiologic'
p302
aS'9 physiologic saline'
p303
aS'NASVAC comprising hepatitis'
p304
aS'vaccine candidate NASVAC'
p305
aS'HBV surface HBsAg'
p306
aS'double blinded placebo'
p307
aS'profile of nasal'
p308
aS'safety and immunogenic'
p309
aS'candidate NASVAC comprising'
p310
aS'core antigens HBcAg'
p311
aS'HBV recombinant antigens'
p312
aS'administration of both'
p313
aS'randomized clinical trial'
p314
aS'markers of immunity'
p315
aS'both HBV recombinant'
p316
aS'according to Good'
p317
aS'guidelines Participants ranged'
p318
aS'immunogenic in animal'
p319
aS'HBsAg and core'
p320
aS'18 to 45'
p321
aS'infection to HBV'
p322
aS'aimed at exploring'
p323
aS'years and were'
p324
aS'allocated to receive'
p325
aS'Practice guidelines Participants'
p326
aS'Good Clinical Practice'
p327
aS'placebo controlled randomized'
p328
aS'ranged in age'
p329
aS'Clinical Practice guidelines'
p330
aS'blinded placebo controlled'
p331
aS'age from 18'
p332
aS'controlled randomized clinical'
p333
aS'virus HBV surface'
p334
aS'Source'
p335
aS'pre and post'
p336
aS'saliva and nasal'
p337
aS'nasal wash samples'
p338
aS'anterior and posterior'
p339
aS'covalently linked'
p340
aS'HBcAg HBsAg'
p341
aS'Antibody response'
p342
aS'healthy volunteers'
p343
aS'National Center'
p344
aS'Accuspray Becton Dickinson'
p345
aS'five'
p346
aS'full length HBcAg'
p347
aS'19'
p348
aS'each type'
p349
aS'total number'
p350
aS'concentration of anti'
p351
aS'reactions were'
p352
aS'more than 10IU'
p353
aS's exact test'
p354
aS'Fisher s exact'
p355
aS'also'
p356
aS'both'
p357
aS'early'
p358
aS'mean anti HBs'
p359
aS'confidence intervals were'
p360
aS'95 confidence intervals'
p361
aS'adverse events included'
p362
aS'linked immunosorbent assay'
p363
aS'enzyme linked immunosorbent'
p364
aS'C and any'
p365
aS'require medical attention'
p366
aS'may require medical'
p367
aS'combined to give'
p368
aS'age'
p369
aS'recombinant'
p370
aS'strong'
p371
aS'adverse events'
p372
aS'administered'
p373
aS'performed'
p374
aS'seroprotective'
p375
aS'respect'
p376
aS'administration'
p377
aS'studied'
p378
aS'mucosal'
p379
aS'unexpected'
p380
aS'patients'
p381
aS'saliva'
p382
aS'double blinded'
p383
aS'approximately'
p384
aS'were randomly'
p385
aS'adverse'
p386
aS'dose schedule'
p387
aS'World Health'
p388
aS'used'
p389
aS'time'
p390
aS'related'
p391
aS'HBV'
p392
aS'participants'
p393
aS'safety'
p394
aS'had'
p395
aS'45'
p396
aS'90'
p397
aS'local'
p398
aS'HBV antigens'
p399
aS'Phase'
p400
aS'most'
p401
aS'first inoculation'
p402
aS'nasal spray'
p403
aS'mixture'
p404
aS'more'
p405
aS'infected patients'
p406
aS'co'
p407
aS'immunogenicity'
p408
aS'populations'
p409
aS'control'
p410
aS'Genetic'
p411
aS'antiviral'
p412
aS'schedule'
p413
aS'addition'
p414
aS'nasal mucosa'
p415
aS'carried'
p416
aS'adults'
p417
aS'dose'
p418
aS'second'
p419
aS'immune'
p420
aS'post immunization'
p421
aS'access'
p422
aS'immune system'
p423
aS'second dose'
p424
aS'Center'
p425
aS'geometric mean'
p426
aS'further'
p427
aS'antigens'
p428
aS'Preclinical'
p429
aS'antibody responses'
p430
aS'relevant'
p431
aS'recorded during'
p432
aS'demonstrated'
p433
aS'vaccine formulation'
p434
aS'devices'
p435
aS'self'
p436
aS'general'
p437
aS'proportion'
p438
aS'serum'
p439
aS'T cell'
p440
aS'study prior'
p441
aS'all'
p442
aS'Figure'
p443
aS'antigen'
p444
aS'days'
p445
aS'full'
p446
aS'detection'
p447
aS'high'
p448
aS'subjects reporting'
p449
aS'18'
p450
aS'mild'
p451
aS'safe well'
p452
aS'first demonstration'
p453
aS'vaccine elicited'
p454
aS'seroprotective anti'
p455
aS'unexpected events'
p456
aS'days 30'
p457
aS'placebo via'
p458
aS'five dose'
p459
aS'two dosages'
p460
aS'total volume'
p461
aS'highly immunogenic'
p462
aS'serologic markers'
p463
aS'immunity infection'
p464
aS'animal models'
p465
aS'performed according'
p466
aS'immunogenic profile'
p467
aS'both HBV'
p468
aS'Good Clinical'
p469
aS'applied'
p470
aS'covalently'
p471
aS'Antibody'
p472
aS'National'
p473
aS'Toxicology'
p474
aS'Carlos'
p475
aS'Anti HBc'
p476
aS'experiments'
p477
aS'immunity against'
p478
aS'95'
p479
aS'Frequency'
p480
aS'participants inoculated'
p481
aS'purified'
p482
aS'were'
p483
aS'data collection'
p484
aS'other nasal'
p485
aS'study nurse'
p486
aS'order'
p487
aS'vaccine were'
p488
aS'shown'
p489
aS'95 confidence'
p490
aS'EM analysis'
p491
aS'development'
p492
aS'sensitivity'
p493
aS'carriers'
p494
aS'single'
p495
aS'responders'
p496
aS'infected'
p497
aS'commercial'
p498
aS'30'
p499
aS'formulation'
p500
aS'75'
p501
aS'Anti'
p502
aS'each dose'
p503
aS'protein'
p504
aS'screening'
p505
aS'reactions'
p506
aS'combined'
p507
aS'Havana'
p508
aS'15'
p509
aS'fourth'
p510
aS'Th1'
p511
aS'same'
p512
aS'7 days'
p513
aS'6h 12h'
p514
aS'undertaken'
p515
aS'axillary'
p516
aS'events'
p517
aS'third'
p518
aS'group'
p519
aS'antibody'
p520
aS'required'
p521
aS'negative'
p522
aS'6h'
p523
aS'need'
p524
aS'increase'
p525
aS'World'
p526
aS'infection'
p527
aS'licensed hepatitis'
p528
aS'double'
p529
aS'frequency'
p530
aS'72h'
p531
aS'headache'
p532
aS'recombinant HBcAg'
p533
aS'All'
p534
aS'sneezing'
p535
aS'achieved'
p536
aS'very'
p537
aS'all participants'
p538
aS'candidate'
p539
aS'one'
p540
aS'induced'
p541
aS'Cuba'
p542
aS'participants were'
p543
aS'reported'
p544
aS'spray'
p545
aS'evaluated'
p546
aS'hematology'
p547
aS'primary'
p548
aS'recorded'
p549
aS'potential'
p550
aS'positive'
p551
aS'elicited'
p552
aS'events were'
p553
aS'tolerated'
p554
aS'revealed'
p555
aS'samples'
p556
aS'licensed'
p557
aS'staff'
p558
aS'device'
p559
aS'data'
p560
aS'collection'
p561
aS'written informed'
p562
aS'recording'
p563
aS'use'
p564
aS'125'
p565
aS'EM'
p566
aS'analysis'
p567
aS'sera'
p568
aS'10IU'
p569
aS'baseline'
p570
aS'successive'
p571
aS'route'
p572
aS'HBc'
p573
aS'HBs'
p574
aS'titers'
p575
aS'developed'
p576
aS'blinded'
p577
aS'blood'
p578
aS'seroprotection'
p579
aS'after'
p580
aS'profile'
p581
aS'days after'
p582
aS'15 30'
p583
aS'7 15'
p584
aS'seroconversion'
p585
aS'vaccines'
p586
aS'B vaccines'
p587
aS'according'
p588
aS'using'
p589
aS'against'
p590
aS'against HBV'
p591
aS'HBV infection'
p592
aS'hypo'
p593
aS'Engineering'
p594
aS'Engineering Biotechnology'
p595
aS'Biotechnology'
p596
aS'volunteer'
p597
aS'nasal adverse'
p598
aS'than'
p599
aS'type'
p600
aS'HBcAg vaccine'
p601
aS'response'
p602
aS'commercial anti'
p603
aS'subjects were'
p604
aS'10'
p605
aS'Adverse'
p606
aS'Adverse events'
p607
aS'rhinorrhea'
p608
aS'stuffiness'
p609
aS'nasal stuffiness'
p610
aS'itching'
p611
aS'palate itching'
p612
aS'palate'
p613
aS'considered'
p614
aS'studies'
p615
aS'abnormalities'
p616
aS'responses against'
p617
aS'responses'
p618
aS'clinically'
p619
aS'self limiting'
p620
aS'limiting'
p621
aS'obtained'
p622
aS'without'
p623
aS'treatment'
p624
aS'planned'
p625
aS'observation period'
p626
aS'doses'
p627
aS'titer'
p628
aS'remained'
p629
aS'group remained'
p630
aS'surface'
p631
aS'system'
p632
aS'present'
p633
aS'geometric'
p634
aS'90 75'
p635
aS'inoculation'
p636
aS'specific'
p637
aS'were mild'
p638
aS'per'
p639
aS'Havana Cuba'
p640
aS'post'
p641
aS'hyper responder'
p642
aS'basic'
p643
aS'g HBcAg'
p644
aS'g HBsAg'
p645
aS'12h'
p646
aS'Participants'
p647
aS'corresponding'
p648
aS'resulted'
p649
aS'event'
p650
aS'during'
p651
aS'seronegative'
p652
aS'standard'
p653
aS'enough'
p654
aS'included sneezing'
p655
aS'2 nasal'
p656
aS'sneezing 34'
p657
aS'12'
p658
aS'8 palate'
p659
aS'8 headache'
p660
aS'34'
p661
aS'1 rhinorrhea'
p662
aS'rhinorrhea 12'
p663
aS'included'
p664
aS'malaise'
p665
aS'remaining'
p666
aS'any local'
p667
aS'rates'
p668
aS'24h'
p669
aS'sample'
p670
aS'administered HBsAg'
p671
aS'activity'
p672
aS'human'
p673
aS'epistaxis'
p674
aS'were more'
p675
aS'HBV vaccine'
p676
aS'following'
p677
aS'sterile'
p678
aS'B virus'
p679
aS'randomized'
p680
aS'sera were'
p681
aS'recipients'
p682
aS'solution'
p683
aS'years'
p684
aS'were recorded'
p685
aS'maximum'
p686
aS'highly'
p687
aS'exploring'
p688
aS'Good'
p689
aS'aimed'
p690
aS'serologic'
p691
aS'receive'
p692
aS'collection sheets'
p693
aS'sheets'
p694
aS'between'
p695
aS'posterior'
p696
aS'cytotoxic'
p697
aS'fifth'
p698
aS'HBsAg following'
p699
aS'linked'
p700
aS'immunized'
p701
aS'HBsAg vaccine'
p702
aS'volunteers immunized'
p703
aS'Drug'
p704
aS'length'
p705
aS'size'
p706
aS'otorhinolaryngologist'
p707
aS'Finlay'
p708
aS'Finlay Hospital'
p709
aS'J Finlay'
p710
aS'Hospital'
p711
aS'confirmed'
p712
aS'adjuvant'
p713
aS'improved'
p714
aS'value'
p715
aS'novel'
p716
aS'drug'
p717
aS'responders anti'
p718
aS'per study'
p719
aS'number'
p720
aS'doses per'
p721
aS'concentration'
p722
aS'treatment group'
p723
aS'Fisher'
p724
aS'enhancement'
p725
aS'written'
p726
aS'based'
p727
aS'severity'
p728
aS'elicit'
p729
aS'work'
p730
aS'history'
p731
aS'potent'
p732
aS'showed'
p733
aS'Nasal administration'
p734
aS'chronic carriers'
p735
aS'HBc seroconversion'
p736
aS'intranasal'
p737
aS'address'
p738
aS'77'
p739
aS'Th cell'
p740
aS'nucleic acids'
p741
aS'previously'
p742
aS'enzyme linked'
p743
aS'expressed'
p744
aS'up'
p745
aS'CIGB'
p746
aS'study staff'
p747
aS'licensed nasal'
p748
aS'give'
p749
aS'formal'
p750
aS'fluorescent'
p751
aS'50g'
p752
aS'M cells'
p753
aS'against HBsAg'
p754
aS'fever'
p755
aS'under'
p756
aS'inflammatory'
p757
aS'significant'
p758
aS'resolving'
p759
aS'effects'
p760
aS'moderate'
p761
aS'received'
p762
aS'there'
p763
aS'over'
p764
aS'differences'
p765
aS'only'
p766
aS'were evaluated'
p767
aS'antibodies'
p768
aS'mucosa'
p769
aS'reporting'
p770
aS'significantly'
p771
aS'Anti HBs'
p772
aS'made'
p773
aS'damage'
p774
aS'ELISA'
p775
aS'ELISA kits'
p776
aS'kits'
p777
aS'observation'
p778
aS'assigned'
p779
aS'Furthermore'
p780
aS'HBV infected'
p781
aS'mean'
p782
aS'assessed'
p783
aS'within'
p784
aS'l per'
p785
aS'hyper'
p786
aS'higher'
p787
aS'serum antibody'
p788
aS'vaccine doses'
p789
aS'71'
p790
aS'mixed'
p791
aS'testing'
p792
aS'Nasal'
p793
aS'Health'
p794
aS'Organization'
p795
aS'Health Organization'
p796
aS'prior'
p797
aS'25'
p798
aS'12h 24h'
p799
aS'24h 48h'
p800
aS'48h 72h'
p801
aS'48h'
p802
aS'actively'
p803
aS'were actively'
p804
aS'actively recorded'
p805
aS'via nasal'
p806
aS'via'
p807
aS'after each'
p808
aS'vaccine dose'
p809
aS'wash'
p810
aS'pre'
p811
aS'defined'
p812
aS'conditions'
p813
aS'level'
p814
aS'NASVAC'
p815
aS'allocated'
p816
aS'saline solution'
p817
aS'saline'
p818
aS'volume'
p819
aS'5ml'
p820
aS'B vaccine'
p821
aS'per nostril'
p822
aS'nostril'
p823
aS'available'
p824
aS'showing'
p825
aS'controlled'
p826
aS'placebo controlled'
p827
aS'male'
p828
aS'healthy male'
p829
aS'methods'
p830
aS'randomly allocated'
p831
aS'randomly'
p832
aS'were also'
p833
aS'similar'
p834
aS'induction'
p835
aS'All subjects'
p836
aS'such'
p837
aS'provided'
p838
aS'component'
p839
aS'frequent'
p840
aS'cases'
p841
aS'measured'
p842
aS'medical'
p843
aS'than 10IU'
p844
aS'DC'
p845
aS'male adults'
p846
aS'test'
p847
aS'Individuals'
p848
aS'clearly'
p849
aS'containing'
p850
aS'Briefly'
p851
aS'thank'
p852
aS'seroprotected'
p853
aS'incubated'
p854
aS'physiologic'
p855
aS'physiologic saline'
p856
aS'comparison'
p857
aS'consent'
p858
aS'informed consent'
p859
aS'informed'
p860
aS'particle'
p861
aS'Recent'
p862
aS'tests'
p863
aS'proportional'
p864
aS'conjugate'
p865
aS'HBc antibodies'
p866
aS'purity'
p867
aS'estimated'
p868
aS'Similarly'
p869
aS'cells'
p870
aS'rats'
p871
aS'Th'
p872
aS'interaction'
p873
aS'nucleic'
p874
aS'neither'
p875
aS'enzyme'
p876
aS'Blood'
p877
aS'CIGB Havana'
p878
aS'particulate'
p879
aS'permanent'
p880
aS'bothersome'
p881
aS'subject'
p882
aS'Recombinant'
p883
aS'levels'
p884
aS'HB'
p885
aS'Heberbiovac HB'
p886
aS'Heberbiovac'
p887
aS'co administration'
p888
aS'hour'
p889
aS'hour after'
p890
aS'between vaccine'
p891
aS'period'
p892
aS'rate'
p893
aS'HBs antibody'
p894
aS'antibody levels'
p895
aS'subtype'
p896
aS'HBsAg subtype'
p897
aS'comprising'
p898
aS'Local'
p899
aS'against HBcAg'
p900
aS'Local site'
p901
aS'site'
p902
aS'through'
p903
aS'100IU'
p904
aS'acute'
p905
aS'Only'
p906
aS'intervals'
p907
aS'There'
p908
aS'There were'
p909
aS'virus HBV'
p910
aS'individuals'
p911
aS'withdrew'
p912
aS'nor'
p913
aS'responder'
p914
aS'adverse reactions'
p915
aS'symptom'
p916
aS'were defined'
p917
aS'nasal flu'
p918
aS'flu'
p919
aS'HBs titers'
p920
aS'were reported'
p921
aS'gene'
p922
aS'temperature'
p923
aS'cell'
p924
aS'following inoculation'
p925
aS'derived'
p926
aS'group withdrew'
p927
aS'inoculated'
p928
aS'needed'
p929
aS'reaction'
p930
aS'comprising HBV'
p931
aS'candidate comprising'
p932
aS'demonstration'
p933
aS'nostril Adverse'
p934
aS'75 All'
p935
aS'Adverse reactions'
p936
aS'titer 10IU'
p937
aS'titers were'
p938
aS'dose Anti'
p939
aS'recorded 1h'
p940
aS'seronegative during'
p941
aS'were all'
p942
aS'remained seronegative'
p943
aS'1h 6h'
p944
aS'evaluated using'
p945
aS'1h'
p946
aS'using corresponding'
p947
aS'HBc titers'
p948
aS'corresponding ELISA'
p949
aS'schedule while'
p950
aS'while'
p951
aS'elicited anti'
p952
aS'tolerated Adverse'
p953
aS'all self'
p954
aS'HBs titer'
p955
aS'reactions included'
p956
aS'dosages'
p957
aS'9 physiologic'
p958
aS'surface HBsAg'
p959
aS'guidelines'
p960
aS'comprising hepatitis'
p961
aS'blinded placebo'
p962
aS'recombinant antigens'
p963
aS'Practice guidelines'
p964
aS'antigens HBcAg'
p965
aS'controlled randomized'
p966
aS'randomized clinical'
p967
aS'models'
p968
aS'Participants ranged'
p969
aS'Clinical'
p970
aS'candidate NASVAC'
p971
aS'ranged'
p972
aS'Practice'
p973
aS'Clinical Practice'
p974
aS'guidelines Participants'
p975
aS'markers'
p976
aS'HBV recombinant'
p977
aS'HBV surface'
p978
aS'NASVAC comprising'
p979
aS'nature'
p980
aS'II'
p981
aS'protective'
p982
aS'wash samples'
p983
aS'protective levels'
p984
aS'dripping'
p985
aS'anterior'
p986
aS'samples were'
p987
aS'adjuvants'
p988
aS'Becton'
p989
aS'Accuspray Becton'
p990
aS'Dickinson'
p991
aS'Accuspray'
p992
aS'Becton Dickinson'
p993
aS'predominated'
p994
aS'conducted'
p995
aS'effect'
p996
aS'length HBcAg'
p997
aS'parenteral'
p998
aS'APCs'
p999
aS'collected'
p1000
aS'UMELISA'
p1001
aS'reported during'
p1002
aS'assay'
p1003
aS'nasally'
p1004
aS'were given'
p1005
aS'given'
p1006
aS'HBc UMELISA'
p1007
aS'products'
p1008
aS's exact'
p1009
aS'exact'
p1010
aS'exact test'
p1011
aS'immune response'
p1012
aS'determinants'
p1013
aS'nurse'
p1014
aS'substrate'
p1015
aS'phosphatase'
p1016
aS'alkaline'
p1017
aS'alkaline phosphatase'
p1018
aS'symptoms'
p1019
aS'doses were'
p1020
aS'mean anti'
p1021
aS'irritating'
p1022
aS'known'
p1023
aS'confidence'
p1024
aS'confidence intervals'
p1025
aS'intervals were'
p1026
aS'Individuals were'
p1027
aS'acids'
p1028
aS'events included'
p1029
aS'Solicited'
p1030
aS'immunosorbent'
p1031
aS'linked immunosorbent'
p1032
aS'immunosorbent assay'
p1033
aS'symptom graded'
p1034
aS'graded'
p1035
aS'interference'
p1036
aS'frequently'
p1037
aS'more frequently'
p1038
aS'medical attention'
p1039
aS'require medical'
p1040
aS'may'
p1041
aS'require'
p1042
aS'attention'
p1043
aS'may require'
p1044
aS'reaction category'
p1045
aS'category'
p1046
aS'state'
p1047
aS'sample size'
p1048
aS'dosages of 125l'
p1049
aS'Th1 response vital'
p1050
aS'cost'
p1051
aS'vital'
p1052
aS'protein in suppressing'
p1053
aS'125l per'
p1054
aS'response vital'
p1055
aS'suppressing'
p1056
aS'125l'
p1057
aS'development of more'
p1058
aS'limited'
p1059
aS'candidate for nasal'
p1060
aS'Solicited systemic adverse'
p1061
aS'HBcAg over nasally'
p1062
aS'seroprotection rate'
p1063
aS'facilities'
p1064
aS'randomized placebo'
p1065
aS'hematology tests'
p1066
aS'annoying may require'
p1067
aS'appetite'
p1068
aS'appetite nausea vomiting'
p1069
aS'years There'
p1070
aS'five vaccine'
p1071
aS'group Sneezing'
p1072
aS'spray calcitonin'
p1073
aS'disability'
p1074
aS'height between'
p1075
aS'two participants'
p1076
aS'usual activity'
p1077
aS'Additionally'
p1078
aS'recording of local'
p1079
aS'within 72hours'
p1080
aS'collected at baseline'
p1081
aS'risk'
p1082
aS'physician'
p1083
aS'terminal'
p1084
aS'dripping nasal stuffiness'
p1085
aS'induce strong HBV'
p1086
aS'measured in saliva'
p1087
aS'ulceration and nasal'
p1088
aS'viral'
p1089
aS'immunization interval'
p1090
aS'antibody titer'
p1091
aS'frequent adverse'
p1092
aS'spray at days'
p1093
aS'high mucosal'
p1094
aS'observations at 6h'
p1095
aS'trial corresponding'
p1096
aS'estimates'
p1097
aS'children became'
p1098
aS'Quality Control CECMED'
p1099
aS'subjects having'
p1100
aS'study indicate'
p1101
aS'even'
p1102
aS'post inoculation'
p1103
aS'More than 97'
p1104
aS'HBcAg to act'
p1105
aS'abnormal baseline biochemistry'
p1106
aS'two moderate adverse'
p1107
aS'study screening'
p1108
aS'18 45 years'
p1109
aS'healthy young adults'
p1110
aS'chemical and basic'
p1111
aS'IgA'
p1112
aS'included fever'
p1113
aS'center randomized'
p1114
aS'antibodies were'
p1115
aS'behavioural changes'
p1116
aS'use Nasal'
p1117
aS'frequency of sneezing'
p1118
aS'more immunogenic'
p1119
aS'approximately 5 10'
p1120
aS'analysis Further'
p1121
aS'cutaneous rash Information'
p1122
aS'protection'
p1123
aS'enough to elicit'
p1124
aS'active'
p1125
aS'human sera Briefly'
p1126
aS'behavioral risk'
p1127
aS'formulation consisting'
p1128
aS'irritating potential acute'
p1129
aS'reports'
p1130
aS'Hospital Havana Cuba'
p1131
aS'taking into consideration'
p1132
aS'were kept under'
p1133
aS'Sera with undetectable'
p1134
aS'Recombinant HBsAg reacts'
p1135
aS'changes'
p1136
aS'antibody levels were'
p1137
aS'antibody were'
p1138
aS'explained'
p1139
aS'recipients at day'
p1140
aS'levels and 95'
p1141
aS'significantly higher'
p1142
aS'study vaccines'
p1143
aS'CTL'
p1144
aS'Individuals were excluded'
p1145
aS'moderate or severe'
p1146
aS'other nasal vaccines'
p1147
aS'specific helper'
p1148
aS'nasal itching palate'
p1149
aS'hospital'
p1150
aS'used in specific'
p1151
aS'sampling including antigen'
p1152
aS'tabulated'
p1153
aS'formulation Sterile physiologic'
p1154
aS'nasally administered drugs'
p1155
aS'125 l per'
p1156
aS'therefore'
p1157
aS'Preclinical studies'
p1158
aS'against HBV nucleocapsid'
p1159
aS'aware'
p1160
aS'98'
p1161
aS'muscle aches decreased'
p1162
aS'populations DC'
p1163
aS'Blood saliva'
p1164
aS'most commonly reported'
p1165
aS'administration also allows'
p1166
aS'97'
p1167
aS'All sera'
p1168
aS'HBeAg'
p1169
aS'race predominated'
p1170
aS'adverse event profile'
p1171
aS'anti HBV vaccine'
p1172
aS'mm'
p1173
aS'corresponding to headache'
p1174
aS'phase monoclonal'
p1175
aS'levels were expressed'
p1176
aS'seroconversion against HBcAg'
p1177
aS'6h and 12h'
p1178
aS'All aspects'
p1179
aS'9 Only'
p1180
aS'HBs titers around'
p1181
aS'indicated'
p1182
aS'HBc specific Th'
p1183
aS'were assigned'
p1184
aS'period following'
p1185
aS'persistently abnormal'
p1186
aS'commercial ultramicroanalytic'
p1187
aS'blood mononuclear cells'
p1188
aS'were classified'
p1189
aS'diseases immunosuppressive disorders'
p1190
aS'immunization Solicited'
p1191
aS'subtype CIGB Havana'
p1192
aS'competitive sequential immunoenzymatic'
p1193
aS'vital for viral'
p1194
aS'HBs anti HBc'
p1195
aS'acemannan'
p1196
aS'severe adverse'
p1197
aS'wash samples All'
p1198
aS'HBs antibody level'
p1199
aS'were monitored'
p1200
aS'block antigenic'
p1201
aS'high responders'
p1202
aS'22nm particle'
p1203
aS'dose of 50'
p1204
aS'polymerase'
p1205
aS'43 subjects signed'
p1206
aS'events were monitored'
p1207
aS'multiple comparisons Geometric'
p1208
aS'only 30 days'
p1209
aS'methods Concurrent comparison'
p1210
aS'Genbank accession number'
p1211
aS'device Accuspray'
p1212
aS'percentage anti'
p1213
aS'group with approximately'
p1214
aS'found in participants'
p1215
aS'were seronegative'
p1216
aS'usual activity frequent'
p1217
aS'seroconversion for anti'
p1218
aS'UMELISA Immunoassay'
p1219
aS'vaccine doses were'
p1220
aS'both antigens Rates'
p1221
aS'vaccines currently licensed'
p1222
aS'chronically'
p1223
aS'before'
p1224
aS'use Nasal spray'
p1225
aS'sequential'
p1226
aS'T lymphocytes CTL'
p1227
aS'randomized placebo controlled'
p1228
aS'production'
p1229
aS'nasal mucosa septum'
p1230
aS'Health Organization standard'
p1231
aS'400'
p1232
aS'methodologies for mucosal'
p1233
aS'contained 0 6ml'
p1234
aS'overcome'
p1235
aS'lymphocytes CTL level'
p1236
aS'antigenic determinants'
p1237
aS'other symptom'
p1238
aS'diseases'
p1239
aS'minimum ensured'
p1240
aS'immunoenzymatic'
p1241
aS'sequential immunoenzymatic assay'
p1242
aS'break'
p1243
aS'inoculation under'
p1244
aS'first hour'
p1245
aS'plates'
p1246
aS'immunogen'
p1247
aS'commercial anti HBV'
p1248
aS'Control'
p1249
aS'achieve protective'
p1250
aS'entire core'
p1251
aS'reasonably'
p1252
aS'classified'
p1253
aS'77 recorded adverse'
p1254
aS'existing antibody against'
p1255
aS'conjugate anti HBs'
p1256
aS'under routine use'
p1257
aS'thin cytoplasm'
p1258
aS'nasal adverse reactions'
p1259
aS'commercial anti HBs'
p1260
aS'per well coated'
p1261
aS'side'
p1262
aS'clinically apparent'
p1263
aS'periodical examinations'
p1264
aS'vaccine group reported'
p1265
aS'surface M cell'
p1266
aS'toxicology or otorhinolaryngology'
p1267
aS'nostril were given'
p1268
aS'very distressing interference'
p1269
aS'glycosylated'
p1270
aS'bleeding Solicited'
p1271
aS'device Accuspray Becton'
p1272
aS'seroprotective response'
p1273
aS'substantially'
p1274
aS'preliminary'
p1275
aS'higher than 10IU'
p1276
aS'network'
p1277
aS'prophylactic vaccines'
p1278
aS'characteristic'
p1279
aS'reported more'
p1280
aS'high responders anti'
p1281
aS'medicine'
p1282
aS'Toxicology CENATOX'
p1283
aS'vaccine antigens'
p1284
aS'screening at day'
p1285
aS'route showing'
p1286
aS'anti HBs anti'
p1287
aS'Conversely patients resolving'
p1288
aS'site adverse'
p1289
aS'monoclonal antibodies'
p1290
aS'day period following'
p1291
aS'B infection'
p1292
aS'cirrhosis'
p1293
aS'Concurrent comparison'
p1294
aS'participants prior'
p1295
aS'toxicity and local'
p1296
aS'HBc seroconversion after'
p1297
aS'detecting'
p1298
aS'were made'
p1299
aS'Sneezing palate itching'
p1300
aS'chronic diseases immunosuppressive'
p1301
aS'showed seroconversion'
p1302
aS'study after obtaining'
p1303
aS'had clinically'
p1304
aS'hematological parameters'
p1305
aS'inoculation Adverse'
p1306
aS'long term consequences'
p1307
aS'CENATOX and Carlos'
p1308
aS'doses were needed'
p1309
aS'mucosa septum'
p1310
aS'were combined'
p1311
aS'persistently abnormal baseline'
p1312
aS'sensitivity Similarly further'
p1313
aS'resolving spontaneously'
p1314
aS'signs nor behavioural'
p1315
aS'computer generated list'
p1316
aS'HBc antibody'
p1317
aS'observations'
p1318
aS'addition to self'
p1319
aS'HBsAgHBcAg'
p1320
aS'percentage'
p1321
aS'recent'
p1322
aS'Anti HBc antibody'
p1323
aS'percentages were compared'
p1324
aS'72h following'
p1325
aS'potential acute toxicity'
p1326
aS'HBsAg and 50g'
p1327
aS'there were more'
p1328
aS'other investigators'
p1329
aS'abnormalities in blood'
p1330
aS'HBs 10'
p1331
aS'vaccine using'
p1332
aS'likely'
p1333
aS'incubated with natural'
p1334
aS'sampling including'
p1335
aS'were mostly reported'
p1336
aS'plasmid'
p1337
aS'antigen presenting cells'
p1338
aS'intervals were estimated'
p1339
aS'enables'
p1340
aS'inoculation of any'
p1341
aS'modulatory'
p1342
aS'clinical situation'
p1343
aS'fashion'
p1344
aS'group Individuals'
p1345
aS'levels against HBsAg'
p1346
aS'renal dialysis patients'
p1347
aS'clinical chemistries'
p1348
aS'adverse events reported'
p1349
aS'collected and categorized'
p1350
aS'populations DC Additionally'
p1351
aS'time intervals'
p1352
aS'same time'
p1353
aS'72h after inoculation'
p1354
aS'Center Havana'
p1355
aS'Briefly UMELISA plates'
p1356
aS'infection Conversely patients'
p1357
aS'Conversely patients'
p1358
aS'nasal formulation'
p1359
aS'access Furthermore'
p1360
aS'month after'
p1361
aS'consequences of chronic'
p1362
aS'subtype obtained'
p1363
aS'Nasal spray devices'
p1364
aS'continuous'
p1365
aS'estimate each rate'
p1366
aS'immunization schedule Following'
p1367
aS'any other symptom'
p1368
aS'well known nasally'
p1369
aS'mouth'
p1370
aS'Two applications per'
p1371
aS'Nine participants'
p1372
aS'immunogenicity profile Recent'
p1373
aS'remaining determinants'
p1374
aS'experiments in mice'
p1375
aS'young adults'
p1376
aS'nucleocapsid'
p1377
aS'age weight'
p1378
aS'potential therapeutic'
p1379
aS'principle'
p1380
aS'75 seroprotection'
p1381
aS'72hours following inoculation'
p1382
aS'order to optimize'
p1383
aS'came'
p1384
aS'per well'
p1385
aS'Nasal administration also'
p1386
aS'value 0 05'
p1387
aS'chills headache'
p1388
aS'studies in mice'
p1389
aS'activity frequent'
p1390
aS'measurement of serum'
p1391
aS'events between'
p1392
aS'effects underlines'
p1393
aS'existing antibody'
p1394
aS'intranasal vaccine'
p1395
aS'devices Accuspray'
p1396
aS'5ml Participants'
p1397
aS'90 days'
p1398
aS'range 18 45'
p1399
aS'placebo study'
p1400
aS'combined prophylactic vaccines'
p1401
aS'aches decreased'
p1402
aS'Volunteers were'
p1403
aS'Preclinical mouse studies'
p1404
aS'natural HBsAg'
p1405
aS'immune compromised hosts'
p1406
aS'rabbit anti HBc'
p1407
aS'nasal adverse events'
p1408
aS'three doses were'
p1409
aS'15 minutes apart'
p1410
aS'pocket'
p1411
aS'severity mild moderate'
p1412
aS'polymerase and envelope'
p1413
aS'antibodies were measured'
p1414
aS'report'
p1415
aS'50g HBcAg'
p1416
aS'devices still need'
p1417
aS'infrequent'
p1418
aS'were instructed'
p1419
aS'microscopy'
p1420
aS'consisting'
p1421
aS'through novel'
p1422
aS'mouth Two'
p1423
aS'local damage'
p1424
aS'adverse events predominated'
p1425
aS'study products were'
p1426
aS'Nine participants received'
p1427
aS'100 showed seroconversion'
p1428
aS'experiments conducted'
p1429
aS'treatment display'
p1430
aS'peripheral'
p1431
aS'core antigen'
p1432
aS'alterations'
p1433
aS'dendritic cell'
p1434
aS'patients with self'
p1435
aS'result'
p1436
aS'access very specialized'
p1437
aS'total of two'
p1438
aS'virus HBV worldwide'
p1439
aS'blood samples were'
p1440
aS'other particulate'
p1441
aS'immunization interval protocol'
p1442
aS'500DC'
p1443
aS'frequent and annoying'
p1444
aS'applications per nostril'
p1445
aS'weak HBV'
p1446
aS'05'
p1447
aS'IU l according'
p1448
aS'also likely'
p1449
aS'core antigen gene'
p1450
aS'completion'
p1451
aS'protected'
p1452
aS'older individuals'
p1453
aS'tolerance'
p1454
aS'Clinically significant events'
p1455
aS'HBcAg molecule'
p1456
aS'were closely'
p1457
aS'glycosylated form'
p1458
aS'terms'
p1459
aS'g derived'
p1460
aS'visualization'
p1461
aS'weak'
p1462
aS'patients resolving acute'
p1463
aS'combined prophylactic'
p1464
aS'per nostril were'
p1465
aS'combined HBsAg'
p1466
aS'local and systemic'
p1467
aS'sterile conditions'
p1468
aS'cells PBMCs'
p1469
aS'medication prior inoculation'
p1470
aS'decreased appetite'
p1471
aS'adults Local'
p1472
aS'tests against'
p1473
aS'commercial recombinant'
p1474
aS'up to 71'
p1475
aS'were not involved'
p1476
aS'nasal dripping nasal'
p1477
aS'basis but adverse'
p1478
aS'made for multiple'
p1479
aS'any symptom graded'
p1480
aS'activity on co'
p1481
aS'reach 75 seroprotection'
p1482
aS'reagents 10'
p1483
aS'flu or other'
p1484
aS'revealed by EM'
p1485
aS'well tolerated safe'
p1486
aS'virus after treatment'
p1487
aS'10IU l seroprotection'
p1488
aS'height'
p1489
aS'frequently reported among'
p1490
aS'Board'
p1491
aS'Samples'
p1492
aS'international units per'
p1493
aS'inflammatory analgesics'
p1494
aS'specific post'
p1495
aS'vessel status after'
p1496
aS'fluorigenic'
p1497
aS'vaccine formulation Sterile'
p1498
aS'basis'
p1499
aS'three'
p1500
aS'5 10'
p1501
aS'severe adverse event'
p1502
aS'acids bound'
p1503
aS'formulation and devices'
p1504
aS'same typical'
p1505
aS'type of cytokine'
p1506
aS'life'
p1507
aS'hospitalization'
p1508
aS'efficacy'
p1509
aS'drugs'
p1510
aS'participants were seronegative'
p1511
aS'adverse effects'
p1512
aS'nasal drug'
p1513
aS'hepatitis B infection'
p1514
aS'exception'
p1515
aS'acceptable local adverse'
p1516
aS'Recombinant HBsAg'
p1517
aS'seroprotection with respect'
p1518
aS'events predominated over'
p1519
aS'titers against'
p1520
aS'spontaneously'
p1521
aS'cause interference'
p1522
aS'other reactions'
p1523
aS'years of age'
p1524
aS'procedure'
p1525
aS'life threatening'
p1526
aS'HBcAg as vaccine'
p1527
aS'Sterile physiologic'
p1528
aS'e g acemannan'
p1529
aS'Among'
p1530
aS'subjects were classified'
p1531
aS'impact of HBcAg'
p1532
aS'characterize'
p1533
aS'category and all'
p1534
aS'kind of vaccine'
p1535
aS'vaccine candidate were'
p1536
aS'Nasal spray'
p1537
aS'mouse'
p1538
aS'l low responders'
p1539
aS'immunogenicity studies'
p1540
aS'reported more frequently'
p1541
aS'resolving acute hepatitis'
p1542
aS'cellular responses'
p1543
aS'reports came'
p1544
aS'HBs alkaline'
p1545
aS'also no clinically'
p1546
aS'adults between'
p1547
aS'response in mice'
p1548
aS'serum clinical chemistry'
p1549
aS'vaccine candidate showed'
p1550
aS'day 30 one'
p1551
aS'independent'
p1552
aS'Genbank accession'
p1553
aS'double blinded study'
p1554
aS'formal hypothesis'
p1555
aS'possible'
p1556
aS'60 days All'
p1557
aS'nucleocapsid polymerase'
p1558
aS'co administered'
p1559
aS'All study products'
p1560
aS'antibodies in human'
p1561
aS'Solicited adverse'
p1562
aS'compared'
p1563
aS'adults between 18'
p1564
aS'kept'
p1565
aS'scenario'
p1566
aS'l All'
p1567
aS'HBV worldwide'
p1568
aS'aqueous and transparent'
p1569
aS'contact'
p1570
aS'otorhinolaryngologist examination'
p1571
aS'were more than'
p1572
aS'phase monoclonal antibodies'
p1573
aS'efficacy of antiviral'
p1574
aS'diarrhea'
p1575
aS'days and 90'
p1576
aS'biochemistry or hematology'
p1577
aS'inversely'
p1578
aS'0 73'
p1579
aS'protocol'
p1580
aS'active immunotherapy'
p1581
aS'third vaccine'
p1582
aS'Serious'
p1583
aS'l according'
p1584
aS'same time intervals'
p1585
aS'l Although anti'
p1586
aS'HBs antibodies were'
p1587
aS'cell populations'
p1588
aS'Genbank'
p1589
aS'ability of HBcAg'
p1590
aS'10 l based'
p1591
aS'2 6 13'
p1592
aS'previous'
p1593
aS'professional antigen presenting'
p1594
aS'HBs 100IU'
p1595
aS'antigens NASVAC'
p1596
aS'impaired T cell'
p1597
aS'devices still'
p1598
aS'0 9 sterile'
p1599
aS'other licensed'
p1600
aS'transformed'
p1601
aS'access very'
p1602
aS'evidenced'
p1603
aS'any general'
p1604
aS'drug behavioral'
p1605
aS'8 general malaise'
p1606
aS'advances'
p1607
aS'Clinically significant'
p1608
aS'weight and height'
p1609
aS'neither clinical adverse'
p1610
aS'screening reasons'
p1611
aS'Induction of immunity'
p1612
aS'expiration through'
p1613
aS'C terminal'
p1614
aS'considered hyper responders'
p1615
aS'All study'
p1616
aS'borosilicate 2R'
p1617
aS'apart'
p1618
aS'volunteers were'
p1619
aS'59'
p1620
aS'dosages of 125'
p1621
aS'Also'
p1622
aS'were registered'
p1623
aS'comparability'
p1624
aS'informative'
p1625
aS'immunosuppressive'
p1626
aS'rats revealed'
p1627
aS'measured by commercial'
p1628
aS'titers against HBsAg'
p1629
aS'improved in terms'
p1630
aS'nasal administration'
p1631
aS'buffer without any'
p1632
aS'million carriers'
p1633
aS'responses in mice'
p1634
aS'had abnormalities'
p1635
aS'blood vessel status'
p1636
aS'antibodies No volunteers'
p1637
aS'fifth vaccine'
p1638
aS'single otorhinolaryngologist'
p1639
aS'HBsAg subtype obtained'
p1640
aS'were excluded'
p1641
aS'received either'
p1642
aS'2 whereas systemic'
p1643
aS'antigen gene under'
p1644
aS'Solicited systemic'
p1645
aS'HBsAg and antibody'
p1646
aS'comments'
p1647
aS'seroprotection percentage'
p1648
aS'acknowledge Enrique Iglesias'
p1649
aS'participants were randomized'
p1650
aS'reasons for screen'
p1651
aS'nasal vaccines'
p1652
aS'HBV nucleocapsid'
p1653
aS'recorded by study'
p1654
aS'race predominated during'
p1655
aS'responders to licensed'
p1656
aS'vaccines plant'
p1657
aS'seroprotection over'
p1658
aS'Further'
p1659
aS'highest frequency'
p1660
aS'healthy male adult'
p1661
aS's visits'
p1662
aS'study were similar'
p1663
aS'presence of nucleic'
p1664
aS'activator enabling'
p1665
aS'need for development'
p1666
aS'months'
p1667
aS'nasal dripping'
p1668
aS'system Adverse events'
p1669
aS'staff or volunteers'
p1670
aS'reported by other'
p1671
aS'anti HBs antibodies'
p1672
aS'common scenario'
p1673
aS'nine participants'
p1674
aS'All anti'
p1675
aS'administration comprising HBsAg'
p1676
aS'under sterile conditions'
p1677
aS'nor induced local'
p1678
aS'blood samples'
p1679
aS'dialysis patients'
p1680
aS'placebo study staff'
p1681
aS'received study drug'
p1682
aS'P rez'
p1683
aS'nasal HBsAg HBcAg'
p1684
aS'internal medicine'
p1685
aS'following administration'
p1686
aS'also allows'
p1687
aS'seroconversion against'
p1688
aS'drug behavioral risk'
p1689
aS'support'
p1690
aS'W3110'
p1691
aS'HBc specific'
p1692
aS'vaccines administered through'
p1693
aS'predominated during'
p1694
aS'subjects received'
p1695
aS'posterior nasal'
p1696
aS'ultramicroanalytic enzyme'
p1697
aS'HBsAg and 50'
p1698
aS'head'
p1699
aS'antibody levels against'
p1700
aS'form'
p1701
aS'particulate nature'
p1702
aS'developed NASVAC'
p1703
aS'failure'
p1704
aS'0038 All reactions'
p1705
aS'trained physician specializing'
p1706
aS'recorded adverse'
p1707
aS'true'
p1708
aS'intervals were used'
p1709
aS'absent'
p1710
aS'formal sample size'
p1711
aS'axillary temperature 38'
p1712
aS'antigen presenting'
p1713
aS'sterile saline'
p1714
aS'group reported'
p1715
aS'until'
p1716
aS'phosphate'
p1717
aS'required intervention'
p1718
aS'Serious adverse events'
p1719
aS'between vaccine formulation'
p1720
aS'medication'
p1721
aS'Depending'
p1722
aS'presenting cells'
p1723
aS'within 72h after'
p1724
aS'substantially different than'
p1725
aS'Organization there were'
p1726
aS'principle of neutralization'
p1727
aS'vaccine candidate containing'
p1728
aS'total anti'
p1729
aS'limiting resolving'
p1730
aS'HBV vaccine such'
p1731
aS'dual behavior'
p1732
aS'single center'
p1733
aS'cirrhosis liver failure'
p1734
aS'Only two'
p1735
aS'any clinical data'
p1736
aS'comparisons Geometric mean'
p1737
aS'HBc antibodies 17'
p1738
aS'septum and mucosal'
p1739
aS'multiple comparisons'
p1740
aS'adverse signs nor'
p1741
aS'immunogenic hepatitis'
p1742
aS'HBs alkaline phosphatase'
p1743
aS'medication prior'
p1744
aS'profile Recent'
p1745
aS'system Adverse'
p1746
aS'Similarly further'
p1747
aS'10IU l low'
p1748
aS'effect of systemic'
p1749
aS'disappeared within'
p1750
aS'events were more'
p1751
aS'vaccines administered'
p1752
aS'Health Organization there'
p1753
aS'toxicological'
p1754
aS'period following administration'
p1755
aS'inability to contact'
p1756
aS'self reporting'
p1757
aS'damage In addition'
p1758
aS'administration of HBV'
p1759
aS'fact'
p1760
aS'single nasal vaccine'
p1761
aS'basic hematology'
p1762
aS'patients include'
p1763
aS'adult'
p1764
aS'recombinant HBcAg Biokit'
p1765
aS'Anti HBc UMELISA'
p1766
aS'detecting at least'
p1767
aS'activated'
p1768
aS'volunteer received'
p1769
aS'after each immunization'
p1770
aS'cirrhosis liver'
p1771
aS'Information on any'
p1772
aS'HBV chronically infected'
p1773
aS'ELISA adapted'
p1774
aS'disorders'
p1775
aS'mechanisms for antigen'
p1776
aS'institution Five'
p1777
aS'seroprotection rate increased'
p1778
aS'spray calcitonin salmon'
p1779
aS'defined as axillary'
p1780
aS'adjuvants gene'
p1781
aS'Two applications'
p1782
aS'functioning may require'
p1783
aS'response to HBsAg'
p1784
aS'solution Although there'
p1785
aS'small volumes'
p1786
aS'similar surveillance'
p1787
aS'virus treatment'
p1788
aS'NASVAC or placebo'
p1789
aS'event rate exceeded'
p1790
aS'doses 85'
p1791
aS'units per'
p1792
aS'used Genbank'
p1793
aS'mean antibody titer'
p1794
aS'well documented state'
p1795
aS'Volunteers'
p1796
aS'anti HBc UMELISA'
p1797
aS'chronic infection Conversely'
p1798
aS'prophylactic'
p1799
aS'antibody against hepatitis'
p1800
aS'cell activator enabling'
p1801
aS'applications per'
p1802
aS'received study'
p1803
aS'derived recombinant'
p1804
aS'reported previously'
p1805
aS'antibodies from serum'
p1806
aS'single center randomized'
p1807
aS'0 No abnormalities'
p1808
aS'absent mild'
p1809
aS'luminal surface through'
p1810
aS'prevent'
p1811
aS'bleeding Solicited systemic'
p1812
aS'48hours'
p1813
aS'intranasal vaccine candidate'
p1814
aS'T cell responses'
p1815
aS'undertaken to determine'
p1816
aS'tests against HBsAg'
p1817
aS'demonstrated seroconversion'
p1818
aS'qualitative detection'
p1819
aS'solution All'
p1820
aS'rash Information'
p1821
aS'seroprotected subjects'
p1822
aS'phosphate buffer'
p1823
aS'blood products'
p1824
aS'nasal administration comprising'
p1825
aS'adult volunteers Written'
p1826
aS'assistance'
p1827
aS'under sterile'
p1828
aS'HBc quantification'
p1829
aS'variables Adverse events'
p1830
aS'very specialized'
p1831
aS'acute toxicity'
p1832
aS'vaccine Furthermore'
p1833
aS'boost'
p1834
aS'than 400 million'
p1835
aS'filled'
p1836
aS'liter IU'
p1837
aS'were administered'
p1838
aS'statistically'
p1839
aS'any adverse'
p1840
aS'HBcAg combined'
p1841
aS'ulceration'
p1842
aS'vaccine candidate developed'
p1843
aS'Havana Cuba All'
p1844
aS'mononuclear cells'
p1845
aS'Each vial'
p1846
aS'groups'
p1847
aS'HBs UMELISA'
p1848
aS'along'
p1849
aS'disappeared'
p1850
aS'HBsAg Recombinant HBsAg'
p1851
aS'immunization further benefit'
p1852
aS'informed consent Individuals'
p1853
aS'Research Ethics Board'
p1854
aS'novel adjuvants'
p1855
aS'significant events'
p1856
aS'development of mucosal'
p1857
aS'events included fever'
p1858
aS'reagents'
p1859
aS'differences between'
p1860
aS'recipients 0 0038'
p1861
aS'administered drugs'
p1862
aS'permanent impairment'
p1863
aS'B virus anti'
p1864
aS'sneezing nasal'
p1865
aS'were found'
p1866
aS'nor behavioural'
p1867
aS'bulbs'
p1868
aS'vaccine using similar'
p1869
aS'remaining determinants After'
p1870
aS'sterile phosphate'
p1871
aS'vaccines vaccines'
p1872
aS'lymphocytes CTL'
p1873
aS'visit'
p1874
aS'optimize'
p1875
aS'mucosal nasal'
p1876
aS'least one'
p1877
aS'scenario in patients'
p1878
aS'HBV core'
p1879
aS'hospital for 48hours'
p1880
aS'response in up'
p1881
aS'normal functioning'
p1882
aS'purified from strain'
p1883
aS'organized'
p1884
aS'acceptable'
p1885
aS'apparent'
p1886
aS'envelope'
p1887
aS'were undertaken'
p1888
aS'Recent developments'
p1889
aS'Subjects were healthy'
p1890
aS'participants as minimum'
p1891
aS'400 million'
p1892
aS'Binomial distribution point'
p1893
aS'recombinant Heberbiovac'
p1894
aS'list of random'
p1895
aS'hospitalizations were'
p1896
aS'borosilicate'
p1897
aS'were negative'
p1898
aS'polyclonal and multi'
p1899
aS'28nm as characterized'
p1900
aS'actively and always'
p1901
aS'cell pockets'
p1902
aS'labeled'
p1903
aS'obtained from serum'
p1904
aS'assay anti HBs'
p1905
aS'contact after'
p1906
aS'all other'
p1907
aS'septum'
p1908
aS'Each vial contained'
p1909
aS'g acemannan'
p1910
aS'were assigned arbitrarily'
p1911
aS'18 and 45'
p1912
aS'sera Briefly'
p1913
aS'T cell immunity'
p1914
aS'tilted backwards'
p1915
aS'detect differences'
p1916
aS'group withdrew voluntarily'
p1917
aS'allowed'
p1918
aS'72h after'
p1919
aS'Induction'
p1920
aS'containing recombinant'
p1921
aS'cells M cells'
p1922
aS'CECMED in Cuba'
p1923
aS'dialysis'
p1924
aS'remaining 19 participants'
p1925
aS'immunity Nasal administration'
p1926
aS'chemical'
p1927
aS'level in patients'
p1928
aS'criterion'
p1929
aS'stored in borosilicate'
p1930
aS'terms of sensitivity'
p1931
aS'further benefit'
p1932
aS'contribute'
p1933
aS'immunomodulation on HBsAg'
p1934
aS'spray device'
p1935
aS'strong mucosal'
p1936
aS'500DC mm'
p1937
aS'applications'
p1938
aS'graded as moderate'
p1939
aS'work efficiently'
p1940
aS'performed periodical'
p1941
aS'designed'
p1942
aS'reactions were self'
p1943
aS'placebo delivered'
p1944
aS'vaccine Heberbiovac HB'
p1945
aS'natural'
p1946
aS'liquid'
p1947
aS'persistent or permanent'
p1948
aS'tryptophan promoter'
p1949
aS'vaccine candidate tested'
p1950
aS'second vaccine doses'
p1951
aS'standard parenteral HBV'
p1952
aS'form HBcAg'
p1953
aS'were healthy male'
p1954
aS'immunogen even without'
p1955
aS'ultramicroanalytic'
p1956
aS'HBs equal'
p1957
aS'typical'
p1958
aS'site adverse events'
p1959
aS'72h following inoculation'
p1960
aS'expressed and purified'
p1961
aS'number X02763'
p1962
aS'appetite nausea'
p1963
aS'products were'
p1964
aS'400 million carriers'
p1965
aS'statistical'
p1966
aS'one adverse'
p1967
aS'still'
p1968
aS'microscopy EM'
p1969
aS'monitor'
p1970
aS'local tolerance All'
p1971
aS'proportion hypo'
p1972
aS'adverse event rate'
p1973
aS'B virus treatment'
p1974
aS'useful to overcome'
p1975
aS'HBV chronic infection'
p1976
aS'included persistently'
p1977
aS'nasal vaccine Furthermore'
p1978
aS'nose or digestive'
p1979
aS'uptake'
p1980
aS'serum antibody response'
p1981
aS'than 400'
p1982
aS'resulted in recent'
p1983
aS'phase antigen'
p1984
aS'protein expressed'
p1985
aS'titers around'
p1986
aS'obtaining'
p1987
aS'bound'
p1988
aS'congestion sneezing'
p1989
aS'were eligible'
p1990
aS'limited HBV'
p1991
aS'acknowledge Enrique'
p1992
aS'HBcAg particles'
p1993
aS'Dawley rats'
p1994
aS'HBcAg Biokit Barcelona'
p1995
aS'conjugate anti'
p1996
aS'term'
p1997
aS'UMELISA Immunoassay Center'
p1998
aS'immunoglobulin within'
p1999
aS'proteins'
p2000
aS'total of 43'
p2001
aS'vaccine only'
p2002
aS'85'
p2003
aS'control group'
p2004
aS'study screening reasons'
p2005
aS'following inoculation Adverse'
p2006
aS'abnormal'
p2007
aS'achieve protective anti'
p2008
aS'balanced'
p2009
aS'sponsor'
p2010
aS'year'
p2011
aS'recombinant HBsAg'
p2012
aS'anti HBc quantification'
p2013
aS'induced local'
p2014
aS'Solid phase'
p2015
aS'limited HBV infection'
p2016
aS'borosilicate 2R bulbs'
p2017
aS'continuous variables'
p2018
aS'doses were administered'
p2019
aS'sneezing nasal itching'
p2020
aS'responses against HBV'
p2021
aS'contained'
p2022
aS'according to otorhinolaryngologist'
p2023
aS'8IU'
p2024
aS'vaccine candidate administered'
p2025
aS'helpful comments'
p2026
aS'virus anti'
p2027
aS'format using'
p2028
aS'sense although three'
p2029
aS'excluded from enrollment'
p2030
aS'million'
p2031
aS'year 2000 Among'
p2032
aS'possibility'
p2033
aS'block antigenic determinants'
p2034
aS'secreted'
p2035
aS'first vaccine'
p2036
aS'reacting with remaining'
p2037
aS'generating more than'
p2038
aS'Enrique Iglesias'
p2039
aS'against both'
p2040
aS'virus control'
p2041
aS'allowed expiration through'
p2042
aS'Participants allocated'
p2043
aS'still need'
p2044
aS'also thank'
p2045
aS'routes'
p2046
aS'therapeutic use'
p2047
aS'itching palate itching'
p2048
aS'event in both'
p2049
aS'B cells'
p2050
aS'Sprague'
p2051
aS'symptoms very'
p2052
aS'variables'
p2053
aS'antibody were assigned'
p2054
aS'subjects showing'
p2055
aS'HBc alkaline phosphatase'
p2056
aS'defined as events'
p2057
aS'trial phase'
p2058
aS'Rates'
p2059
aS'periodical'
p2060
aS'comprises'
p2061
aS'100 showed'
p2062
aS'5 More than'
p2063
aS'one adverse event'
p2064
aS'transient nasal conditions'
p2065
aS'group included'
p2066
aS'vaccine or placebo'
p2067
aS'nasal itching'
p2068
aS'nasal spray calcitonin'
p2069
aS'impairment or damage'
p2070
aS'indicate'
p2071
aS'candidate containing recombinant'
p2072
aS'recognize any'
p2073
aS'white'
p2074
aS'cell populations DC'
p2075
aS'systemic immunity Nasal'
p2076
aS'Sneezing'
p2077
aS'mostly'
p2078
aS'II clinical studies'
p2079
aS'either NASVAC'
p2080
aS'immunomodulation'
p2081
aS'even without'
p2082
aS'study personnel before'
p2083
aS'alone or mixed'
p2084
aS'HBcAg CIGB'
p2085
aS'control Recombinant'
p2086
aS'clinical adverse signs'
p2087
aS'9 8 general'
p2088
aS'control Recombinant HBcAg'
p2089
aS'seroconversion after immunization'
p2090
aS'any study'
p2091
aS'13'
p2092
aS'effective'
p2093
aS'17'
p2094
aS'expressed as international'
p2095
aS'Five doses'
p2096
aS'institution Five doses'
p2097
aS'medical consultations'
p2098
aS'typical sandwich'
p2099
aS'within 72h'
p2100
aS'outcome'
p2101
aS'other symptom graded'
p2102
aS'addition of HBcAg'
p2103
aS'under observation'
p2104
aS'HBs or anti'
p2105
aS'other mucosal adjuvant'
p2106
aS'pre existing antibody'
p2107
aS'HBsAg reacts'
p2108
aS'rate percentages were'
p2109
aS'peptide vaccine'
p2110
aS'underlines'
p2111
aS'90 of children'
p2112
aS'up to 20'
p2113
aS'sensitivity Similarly'
p2114
aS'immunogen even'
p2115
aS'30 to get'
p2116
aS'instructed'
p2117
aS'19 participants'
p2118
aS'performance'
p2119
aS'impairment'
p2120
aS'l low'
p2121
aS'analysis Further antigenicity'
p2122
aS'HBV infected patients'
p2123
aS'multiple'
p2124
aS'trace'
p2125
aS'specific Th'
p2126
aS'Biotechnology in Havana'
p2127
aS'50g HBsAg'
p2128
aS'gene under'
p2129
aS'molecule'
p2130
aS'0 5ml Participants'
p2131
aS'study 100'
p2132
aS'positive or negative'
p2133
aS'detect'
p2134
aS'significantly increases'
p2135
aS'previous findings'
p2136
aS'Th1 type'
p2137
aS'characteristic of HBV'
p2138
aS'cellular responses against'
p2139
aS'adverse signs'
p2140
aS'participant s head'
p2141
aS'Becton Dickinson Depending'
p2142
aS'determinants After'
p2143
aS'renal'
p2144
aS'without any adjuvant'
p2145
aS'majority of infected'
p2146
aS'professional'
p2147
aS'were expressed'
p2148
aS'estimated by treatment'
p2149
aS'rate percentages'
p2150
aS'substantially different'
p2151
aS'virus as well'
p2152
aS'severity Binomial distribution'
p2153
aS'accession'
p2154
aS'parenteral administered HBsAg'
p2155
aS'tryptophan'
p2156
aS'HBsAg titer'
p2157
aS'events 58'
p2158
aS'ratio'
p2159
aS'All blood'
p2160
aS'male adult volunteers'
p2161
aS'study group included'
p2162
aS'potential acute'
p2163
aS'otorhinolaryngology'
p2164
aS'Concurrent'
p2165
aS'Binomial'
p2166
aS'Severe reactions were'
p2167
aS'HBs protective levels'
p2168
aS'previously for other'
p2169
aS'showed protective levels'
p2170
aS'More than'
p2171
aS'get'
p2172
aS'history of hepatitis'
p2173
aS'reported among'
p2174
aS'mixed with other'
p2175
aS'candidate demonstrated'
p2176
aS'ultramicroanalytic enzyme linked'
p2177
aS'S protein expressed'
p2178
aS'13 excess'
p2179
aS'secondary'
p2180
aS'same typical sandwich'
p2181
aS'regarding'
p2182
aS'vaccine Furthermore participants'
p2183
aS'age of participants'
p2184
aS'axillary temperature 39'
p2185
aS'symptom bothersome'
p2186
aS'physicians or volunteers'
p2187
aS'infection resolving'
p2188
aS'M cells transport'
p2189
aS'were used'
p2190
aS'true adverse event'
p2191
aS'audited'
p2192
aS'frequency of local'
p2193
aS'HBV core HBc'
p2194
aS'HBV nucleocapsid polymerase'
p2195
aS'adapted to small'
p2196
aS'sterile aqueous'
p2197
aS'cell immune response'
p2198
aS'per liter IU'
p2199
aS'2IU'
p2200
aS'licensed HBV'
p2201
aS'Hospital Havana'
p2202
aS'Organization standard'
p2203
aS'itching rhinorrhea nasal'
p2204
aS'investigators with licensed'
p2205
aS'study one subject'
p2206
aS'one month'
p2207
aS'blood screening regarding'
p2208
aS'candidate were'
p2209
aS'seronegative for anti'
p2210
aS'diarrhea and cutaneous'
p2211
aS'total of 77'
p2212
aS'mostly reported'
p2213
aS'1 hour'
p2214
aS'subjects were considered'
p2215
aS'similar surveillance methods'
p2216
aS'therapies'
p2217
aS'schedule Following administration'
p2218
aS'moderate adverse events'
p2219
aS'healthy adults Local'
p2220
aS'fluorescent signal'
p2221
aS'B vaccine candidate'
p2222
aS'personnel before'
p2223
aS'screen'
p2224
aS'g acemannan Whether'
p2225
aS'induced serum antibody'
p2226
aS'gratefully'
p2227
aS'chemistries and hematology'
p2228
aS'steroid'
p2229
aS'Each'
p2230
aS'also contribute'
p2231
aS'both reports came'
p2232
aS'HBsAg Recombinant'
p2233
aS'vaccine and one'
p2234
aS'purified recombinant'
p2235
aS'very specialized mechanisms'
p2236
aS'Sterile'
p2237
aS'vaccine were given'
p2238
aS'analgesics'
p2239
aS'residence'
p2240
aS'events did'
p2241
aS'more frequently reported'
p2242
aS'enabling'
p2243
aS'Chronic'
p2244
aS'participants were instructed'
p2245
aS'predominated over'
p2246
aS'induce strong'
p2247
aS'nor behavioural changes'
p2248
aS'vaccine recipients achieved'
p2249
aS'further studies'
p2250
aS'preclinical studies'
p2251
aS'Iglesias'
p2252
aS'immunity in chronic'
p2253
aS'were compared'
p2254
aS'77 adverse'
p2255
aS'studies were conducted'
p2256
aS'stored'
p2257
aS'them were'
p2258
aS'Recent advances'
p2259
aS'sampling'
p2260
aS'itching rhinorrhea'
p2261
aS'undetectable anti'
p2262
aS'most frequent adverse'
p2263
aS'considering'
p2264
aS'anosmia'
p2265
aS'achieved by nasal'
p2266
aS'Research'
p2267
aS'purified with recombinant'
p2268
aS'tonsils'
p2269
aS'registered Only'
p2270
aS'HBsAg and 100'
p2271
aS'antiviral immunogenicity'
p2272
aS'stuffiness and epistaxis'
p2273
aS'Clinically'
p2274
aS'immunopotentiating activity'
p2275
aS'sponsor institution'
p2276
aS'Subjects were'
p2277
aS'over systemic reactions'
p2278
aS'anti HBs 10'
p2279
aS'parenteral HBV'
p2280
aS'careful'
p2281
aS'73 provided'
p2282
aS'apparent abnormalities visualized'
p2283
aS'Biokit Barcelona Spain'
p2284
aS'plant derived vaccines'
p2285
aS'nasal flu vaccine'
p2286
aS'distressing'
p2287
aS'efficiently'
p2288
aS'T lymphocytes'
p2289
aS'buffer without'
p2290
aS'Spain'
p2291
aS'regarding chemical'
p2292
aS'vaccine doses Local'
p2293
aS'frequently in participants'
p2294
aS'region'
p2295
aS'clinically apparent abnormalities'
p2296
aS'used to estimate'
p2297
aS'HBc alkaline'
p2298
aS'within 72hours following'
p2299
aS'Iglesias P rez'
p2300
aS'compared by Fisher'
p2301
aS'them'
p2302
aS'equal'
p2303
aS'strain'
p2304
aS'good'
p2305
aS'inversely proportional'
p2306
aS'patients and carriers'
p2307
aS'were stored'
p2308
aS'long term'
p2309
aS'alterations or transient'
p2310
aS'diluted in sterile'
p2311
aS'helpful comments Finally'
p2312
aS'congestion sneezing nasal'
p2313
aS'encouraging taking'
p2314
aS'different'
p2315
aS'participant'
p2316
aS'through novel routes'
p2317
aS'spray device Accuspray'
p2318
aS'doctor'
p2319
aS'formulations'
p2320
aS'All but two'
p2321
aS'electron microscopy EM'
p2322
aS'surveillance'
p2323
aS'induction of immunity'
p2324
aS'further immunogenicity studies'
p2325
aS'full length recombinant'
p2326
aS'status'
p2327
aS'internal medicine toxicology'
p2328
aS'commonly reported'
p2329
aS'levels were'
p2330
aS'particulate antigens'
p2331
aS'0 0038 All'
p2332
aS'IU'
p2333
aS'formulation Phase II'
p2334
aS'Barcelona'
p2335
aS'route showing induction'
p2336
aS'sample size nine'
p2337
aS'l in order'
p2338
aS'seroprotected subjects were'
p2339
aS'total serum antibody'
p2340
aS'self limiting resolving'
p2341
aS'evaluated in duplicate'
p2342
aS'very encouraging'
p2343
aS'eligible'
p2344
aS'defined as absent'
p2345
aS'chronic patients include'
p2346
aS'became chronic carriers'
p2347
aS'steroid anti inflammatory'
p2348
aS'baseline 30'
p2349
aS'studies with HBsAg'
p2350
aS'other commercial'
p2351
aS'were more frequently'
p2352
aS'findings in experiments'
p2353
aS'cell immunity'
p2354
aS'inability'
p2355
aS'placebo group 59'
p2356
aS'g nasal flu'
p2357
aS'persistently'
p2358
aS'reporting adverse events'
p2359
aS'sprayed'
p2360
aS'Only anti HBs'
p2361
aS'levels against'
p2362
aS'among'
p2363
aS'adjustments'
p2364
aS'local or systemic'
p2365
aS'cytotoxic T cell'
p2366
aS'showed protective'
p2367
aS'Solicited adverse events'
p2368
aS'all participants were'
p2369
aS'behavioural'
p2370
aS'72hours following'
p2371
aS'comparisons Geometric'
p2372
aS'infrequent Adverse events'
p2373
aS'rats revealed neither'
p2374
aS'strong mucosal immunogenicity'
p2375
aS'patients include combined'
p2376
aS'placebo All study'
p2377
aS'immunogenicity of nasal'
p2378
aS'such samples'
p2379
aS'90 day period'
p2380
aS'Ethics'
p2381
aS'antigenicity studies'
p2382
aS'aspects'
p2383
aS'around'
p2384
aS'blinded fashion'
p2385
aS'mucosal alterations'
p2386
aS'were monitored over'
p2387
aS'recipient'
p2388
aS'90 applied doses'
p2389
aS'infected patient'
p2390
aS'were estimated pre'
p2391
aS'aqueous'
p2392
aS'irritating nor induced'
p2393
aS'corroborates previous'
p2394
aS'failures included'
p2395
aS'45 years There'
p2396
aS'envelope proteins'
p2397
aS'benefit'
p2398
aS'Subjects'
p2399
aS'either'
p2400
aS'hematology values'
p2401
aS'side effects'
p2402
aS'reported by 15'
p2403
aS'64'
p2404
aS'voluntarily'
p2405
aS'partial efficacy'
p2406
aS'recognize'
p2407
aS'candidate whereas systemic'
p2408
aS'50 g derived'
p2409
aS'than 97'
p2410
aS'than 95'
p2411
aS'influenza nasal flu'
p2412
aS'assay ELISA adapted'
p2413
aS'immunization with HBsAg'
p2414
aS'ability'
p2415
aS'HBcAg considering'
p2416
aS'HBsAg alone'
p2417
aS'doses Local'
p2418
aS'response to major'
p2419
aS'dependent and independent'
p2420
aS'specializing'
p2421
aS'allocation All'
p2422
aS'palate itching anosmia'
p2423
aS'cytotoxic T lymphocytes'
p2424
aS'chronic HBV infection'
p2425
aS'visits'
p2426
aS'7 years range'
p2427
aS'solid phase monoclonal'
p2428
aS'50 g purified'
p2429
aS'PBMCs from patients'
p2430
aS'nasal vaccine formulation'
p2431
aS'fifth dose'
p2432
aS'25 showed'
p2433
aS'categorized by body'
p2434
aS'cost and side'
p2435
aS'post immunization sera'
p2436
aS'apart All subjects'
p2437
aS'mice reconstituted'
p2438
aS'pockets'
p2439
aS'act'
p2440
aS'local tolerance'
p2441
aS'code labeled'
p2442
aS'Information'
p2443
aS'other mucosal'
p2444
aS'prolonged hospitalization'
p2445
aS'study and control'
p2446
aS'without any'
p2447
aS'major HBV'
p2448
aS'terminal region'
p2449
aS'trial were'
p2450
aS'HBsAg 10IU'
p2451
aS'immunogenicity Preclinical'
p2452
aS'determine'
p2453
aS'immunization further'
p2454
aS'intervention'
p2455
aS'proportion hypo responders'
p2456
aS'conflict of interest'
p2457
aS'g derived recombinant'
p2458
aS'g influenza nasal'
p2459
aS'than 95 purity'
p2460
aS'underwent pre study'
p2461
aS'enhancement observed'
p2462
aS'low'
p2463
aS'days All sera'
p2464
aS'secretion'
p2465
aS'needed to reach'
p2466
aS'30 Thirty'
p2467
aS'were self limiting'
p2468
aS'also allows interaction'
p2469
aS'professional antigen'
p2470
aS'Individuals were eligible'
p2471
aS'hyper responders'
p2472
aS'l One recipient'
p2473
aS'HBs anti'
p2474
aS'human clinical'
p2475
aS'physician specializing'
p2476
aS'antigenicity studies were'
p2477
aS'first report'
p2478
aS'combined formulations'
p2479
aS'Sprague Dawley'
p2480
aS'antigen gene'
p2481
aS'temperature 38'
p2482
aS'labeled matched pre'
p2483
aS'surface and core'
p2484
aS'side effects underlines'
p2485
aS'were conducted'
p2486
aS'dose however five'
p2487
aS'dose schedule formulation'
p2488
aS'inoculation Blood'
p2489
aS'wash samples were'
p2490
aS'interval'
p2491
aS'USA'
p2492
aS'l Sera'
p2493
aS'measurement'
p2494
aS'reporting adverse'
p2495
aS'blood mononuclear'
p2496
aS'enable'
p2497
aS'Th1 response'
p2498
aS'point estimates'
p2499
aS'size of 28nm'
p2500
aS'nasally administered'
p2501
aS'recombinant full'
p2502
aS'biochemistry'
p2503
aS'2000'
p2504
aS'underwent pre'
p2505
aS'efficiently as primary'
p2506
aS'comments Finally'
p2507
aS'pre incubated'
p2508
aS'More'
p2509
aS'presenting'
p2510
aS'requested'
p2511
aS'antibody titers'
p2512
aS'Preclinical toxicological studies'
p2513
aS'otorhinolaryngology Neither'
p2514
aS'more than 95'
p2515
aS'potent immunogen'
p2516
aS'post inoculation adverse'
p2517
aS'specializing in internal'
p2518
aS'each nostril'
p2519
aS'vaccine candidate demonstrated'
p2520
aS'irritating nor'
p2521
aS'any general reaction'
p2522
aS'documented state'
p2523
aS'liquid Each'
p2524
aS'event profile under'
p2525
aS'Briefly UMELISA'
p2526
aS'mixed with 50'
p2527
aS'were recruited'
p2528
aS'immunoglobulin'
p2529
aS'placebo All'
p2530
aS'behavioral'
p2531
aS'other developed'
p2532
aS'per liter'
p2533
aS'influenza'
p2534
aS'estimated pre'
p2535
aS'consider'
p2536
aS'more immunogenic hepatitis'
p2537
aS'caused'
p2538
aS'withdrew voluntarily'
p2539
aS'month'
p2540
aS'vaccines currently'
p2541
aS'25 showed protective'
p2542
aS'first and second'
p2543
aS'basic hematological'
p2544
aS'HBsAgHBcAg vaccine'
p2545
aS'tabulated by time'
p2546
aS'related to any'
p2547
aS'children'
p2548
aS'2R bulbs'
p2549
aS'monitored over'
p2550
aS'two seroprotected'
p2551
aS'frequent adverse events'
p2552
aS'entire core antigen'
p2553
aS'events predominated'
p2554
aS'novel adjuvants gene'
p2555
aS'cells APCs'
p2556
aS'HBcAg had'
p2557
aS'risk factors'
p2558
aS'M cell'
p2559
aS'liter'
p2560
aS'geometric mean anti'
p2561
aS'1 to vaccine'
p2562
aS'induce'
p2563
aS'All reactions'
p2564
aS'get 25'
p2565
aS'device Also'
p2566
aS'HBcAg nasal'
p2567
aS'viral clearance'
p2568
aS'difference'
p2569
aS'similar proportion'
p2570
aS'head tilted'
p2571
aS'any adverse event'
p2572
aS'children became chronic'
p2573
aS'90 days following'
p2574
aS'list'
p2575
aS'prolonged'
p2576
aS'recipients one month'
p2577
aS'were registered Only'
p2578
aS'HBsAg used'
p2579
aS'small'
p2580
aS'infection resolving spontaneously'
p2581
aS'vaccines vaccines administered'
p2582
aS'surveillance methods Concurrent'
p2583
aS'revealed neither'
p2584
aS'antibodies and 25'
p2585
aS'seroprotective antibody titers'
p2586
aS'medical monitor'
p2587
aS'Similarly further assays'
p2588
aS'within 6 months'
p2589
aS'parenteral administered'
p2590
aS'Havana Cuba licensed'
p2591
aS'good safety'
p2592
aS'functioning'
p2593
aS'very distressing'
p2594
aS'enough to cause'
p2595
aS'immunization sera Only'
p2596
aS'10 l per'
p2597
aS'hour after each'
p2598
aS'reconstituted with peripheral'
p2599
aS'Engineering Biotechnology Havana'
p2600
aS'presence'
p2601
aS'samples All'
p2602
aS'behavioral risk factors'
p2603
aS'vomiting'
p2604
aS'events reported'
p2605
aS'animals under'
p2606
aS'HB CIGB'
p2607
aS'excess'
p2608
aS'planned medical consultations'
p2609
aS'nasal drug behavioral'
p2610
aS'significant acute'
p2611
aS'rate exceeded 15'
p2612
aS'immunity against HBV'
p2613
aS'Phase II'
p2614
aS'concluded at day'
p2615
aS'allows'
p2616
aS'after treatment'
p2617
aS'levels of anti'
p2618
aS'vaccine studies'
p2619
aS'novel routes'
p2620
aS'period and severity'
p2621
aS'antibody responses against'
p2622
aS'0 6ml'
p2623
aS'g Miacalcin nasal'
p2624
aS'dose injection'
p2625
aS'chronically infected'
p2626
aS'involved in collection'
p2627
aS'toxicity'
p2628
aS'All subjects received'
p2629
aS'patients resolving'
p2630
aS'more than 400'
p2631
aS'were also collected'
p2632
aS'volunteers Written informed'
p2633
aS'placebo group Individuals'
p2634
aS'pockets enable'
p2635
aS'anosmia nasal'
p2636
aS'immunoenhancing'
p2637
aS'surveillance methods'
p2638
aS'events within'
p2639
aS'commercial recombinant HBcAg'
p2640
aS'immunosuppressive disorders'
p2641
aS'trained'
p2642
aS'calcitonin salmon Novartis'
p2643
aS'mononuclear'
p2644
aS'containing recombinant hepatitis'
p2645
aS'alkaline phosphatase conjugate'
p2646
aS'B cell activator'
p2647
aS'clearly demonstrates'
p2648
aS'l for analysis'
p2649
aS'interval protocol'
p2650
aS'CTL level'
p2651
aS'intervention to prevent'
p2652
aS'received either NASVAC'
p2653
aS'geometric mean antibody'
p2654
aS'available for testing'
p2655
aS'were requested'
p2656
aS'outpatient'
p2657
aS'Drug Quality Control'
p2658
aS'tested'
p2659
aS'anti HBs ELISA'
p2660
aS'were mild self'
p2661
aS'cell dependent'
p2662
aS'Cuba licensed hepatitis'
p2663
aS'drug over'
p2664
aS'administration of successive'
p2665
aS'avoid anterior'
p2666
aS'strong HBV core'
p2667
aS'mean antibody'
p2668
aS'placebo controlled double'
p2669
aS'support further phase'
p2670
aS'l and high'
p2671
aS'nine'
p2672
aS'mostly reported during'
p2673
aS'any symptom'
p2674
aS'well coated'
p2675
aS'fever chills headache'
p2676
aS'volunteer received either'
p2677
aS'include combined'
p2678
aS'antigens Rates'
p2679
aS'group sample size'
p2680
aS'observation period concluded'
p2681
aS'All blood samples'
p2682
aS'potential therapeutic use'
p2683
aS'minimum'
p2684
aS'higher than'
p2685
aS'numbers'
p2686
aS'tract'
p2687
aS'sense'
p2688
aS'HBsAg immunogenicity'
p2689
aS'activated B cells'
p2690
aS'developed antibodies'
p2691
aS'inoculation under sterile'
p2692
aS'against both antigens'
p2693
aS'baseline all participants'
p2694
aS'antibodies against HBsAg'
p2695
aS'fluorigenic substrate'
p2696
aS'defined as concentration'
p2697
aS'multi specific'
p2698
aS'hypo responders'
p2699
aS'titer Anti'
p2700
aS'cases of fever'
p2701
aS'l in such'
p2702
aS'activator'
p2703
aS'routine use'
p2704
aS'plant'
p2705
aS'sandwich'
p2706
aS'percentages were'
p2707
aS'mild No development'
p2708
aS's head tilted'
p2709
aS'known nasally administered'
p2710
aS'true adverse'
p2711
aS'otorhinolaryngologist performed periodical'
p2712
aS'two seroprotected vaccine'
p2713
aS'buffer'
p2714
aS'enables antigens'
p2715
aS'Withdrawal'
p2716
aS'There were also'
p2717
aS'l based'
p2718
aS'results indicated'
p2719
aS'recombinant full length'
p2720
aS'ELISA kits Samples'
p2721
aS'rhinorrhea nasal stuffiness'
p2722
aS'superior to 95'
p2723
aS'chemistries'
p2724
aS'chronically infected patients'
p2725
aS'transient nasal'
p2726
aS'failures included persistently'
p2727
aS'safety and preliminary'
p2728
aS'T cell dependent'
p2729
aS'signs nor'
p2730
aS'enabling activated'
p2731
aS'specific post inoculation'
p2732
aS'group included sneezing'
p2733
aS'cell activator'
p2734
aS'between 18'
p2735
aS'made actively'
p2736
aS'signs'
p2737
aS'HBsAgHBcAg vaccine candidate'
p2738
aS'gratefully acknowledge Enrique'
p2739
aS'20'
p2740
aS'5ml Participants allocated'
p2741
aS'luminal surface'
p2742
aS'UMELISA plates 10'
p2743
aS'nasal immunization'
p2744
aS'moderate adverse'
p2745
aS'detected'
p2746
aS'were available'
p2747
aS'Local site adverse'
p2748
aS'volunteer generating more'
p2749
aS'placebo developed'
p2750
aS'antibody response'
p2751
aS'HBsAg mixed'
p2752
aS'drugs of protein'
p2753
aS'2R'
p2754
aS'effective approach'
p2755
aS'baseline 30 days'
p2756
aS'encouraging'
p2757
aS'medicine toxicology'
p2758
aS'unexpected or severe'
p2759
aS'Immunoassay Center'
p2760
aS'cell pockets enable'
p2761
aS'generating more'
p2762
aS'natural HBsAg subtype'
p2763
aS'g influenza'
p2764
aS'HBcAg Biokit'
p2765
aS'seroprotected vaccine recipients'
p2766
aS'became chronic'
p2767
aS'palate itching rhinorrhea'
p2768
aS'determine mucosal'
p2769
aS'antibodies 17'
p2770
aS'always'
p2771
aS'assistance and helpful'
p2772
aS'Further antigenicity studies'
p2773
aS'Only anti'
p2774
aS'did'
p2775
aS'collection of any'
p2776
aS'obtaining written informed'
p2777
aS'found'
p2778
aS'difficult'
p2779
aS'were collected'
p2780
aS'characterized'
p2781
aS'defects'
p2782
aS'excess over'
p2783
aS'Following administration'
p2784
aS'tilted'
p2785
aS'weight'
p2786
aS'undetectable'
p2787
aS'HBsAg antigen'
p2788
aS'considered statistically significant'
p2789
aS'present formulation Phase'
p2790
aS'temperature 39'
p2791
aS'antibodies Thus most'
p2792
aS'moderate and severe'
p2793
aS'licensed nasal vaccine'
p2794
aS'moderate symptom bothersome'
p2795
aS'20 of healthy'
p2796
aS'volunteers Written'
p2797
aS'Drug Administration'
p2798
aS'permanent disability'
p2799
aS'low responders anti'
p2800
aS'toxicological studies'
p2801
aS'vomiting diarrhea'
p2802
aS'29'
p2803
aS'frequently reported'
p2804
aS'months of study'
p2805
aS'Geometric mean anti'
p2806
aS'study one'
p2807
aS'mucosal irritating potential'
p2808
aS'severe Local site'
p2809
aS'age Volunteers were'
p2810
aS'issue'
p2811
aS'transport antigens'
p2812
aS'renal dialysis'
p2813
aS'each treatment'
p2814
aS'patients or chronic'
p2815
aS'According'
p2816
aS'mild symptom present'
p2817
aS'specialized mechanisms'
p2818
aS'Phase II clinical'
p2819
aS'Nine'
p2820
aS'19 included'
p2821
aS'immunity against HBcAg'
p2822
aS'mucosal blood vessel'
p2823
aS'registered Only two'
p2824
aS'phosphate buffer without'
p2825
aS'allocation'
p2826
aS'antigenic'
p2827
aS'single otorhinolaryngologist performed'
p2828
aS'fever were registered'
p2829
aS'studies HBcAg'
p2830
aS'age Volunteers'
p2831
aS'seroprotective antibody'
p2832
aS'currently licensed'
p2833
aS'g purified'
p2834
aS'accession number X02763'
p2835
aS'Recombinant HBcAg'
p2836
aS'Severe reactions'
p2837
aS'major'
p2838
aS'consultations'
p2839
aS'probability'
p2840
aS'resulting HBcAg'
p2841
aS'0 73 provided'
p2842
aS'reacts with solid'
p2843
aS'Quality Control'
p2844
aS'any clinical'
p2845
aS'detection of total'
p2846
aS'two participants completed'
p2847
aS'eight recipients'
p2848
aS'mouth Two applications'
p2849
aS'including antigen'
p2850
aS'trial no formal'
p2851
aS'mixture of 50g'
p2852
aS'HBsAg significantly'
p2853
aS'cell and antibody'
p2854
aS'threatening'
p2855
aS'least'
p2856
aS'changes in animals'
p2857
aS'Dickinson were filled'
p2858
aS'well documented'
p2859
aS'majority'
p2860
aS'compartment'
p2861
aS'9 sterile'
p2862
aS'chills headache muscle'
p2863
aS'participants needed'
p2864
aS'dose and between'
p2865
aS'general reaction'
p2866
aS'react with antibodies'
p2867
aS'approximately 500DC'
p2868
aS'immunogenicity profile'
p2869
aS'undetectable anti HBs'
p2870
aS'immediate'
p2871
aS'basal'
p2872
aS'neutralization'
p2873
aS'strong HBV'
p2874
aS'study support further'
p2875
aS'Food and Drug'
p2876
aS'defects in dendritic'
p2877
aS'Biokit'
p2878
aS'were mostly'
p2879
aS'against hepatitis'
p2880
aS'kind'
p2881
aS'75 By comparison'
p2882
aS'vial'
p2883
aS'30 Thirty days'
p2884
aS'characterized by electron'
p2885
aS'profile under'
p2886
aS'administered by day'
p2887
aS'vaccine and peptide'
p2888
aS'declare'
p2889
aS'antigen sampling including'
p2890
aS'Cuba All'
p2891
aS'CENATOX'
p2892
aS'HBeAg in saliva'
p2893
aS'immunogenicity Preclinical mouse'
p2894
aS'72hours'
p2895
aS'fixed volume'
p2896
aS'Dawley rats revealed'
p2897
aS'fever were'
p2898
aS'period concluded'
p2899
aS'showing antibody levels'
p2900
aS'glycosylated form HBcAg'
p2901
aS'dendritic'
p2902
aS'categorized'
p2903
aS'0038 All'
p2904
aS'assay anti'
p2905
aS'antibodies against'
p2906
aS'C until'
p2907
aS'virus control Recombinant'
p2908
aS'using similar surveillance'
p2909
aS'immunodominant antigen'
p2910
aS'internal'
p2911
aS'Baseline comparability'
p2912
aS'achieved anti HBs'
p2913
aS'after treatment display'
p2914
aS'specific Th cell'
p2915
aS'Written informed consent'
p2916
aS'added'
p2917
aS'severity mild'
p2918
aS'flu vaccine'
p2919
aS'intensity and 98'
p2920
aS'reach'
p2921
aS'developed antibodies against'
p2922
aS'react'
p2923
aS'commercial ultramicroanalytic enzyme'
p2924
aS'73'
p2925
aS'moderate symptom'
p2926
aS'approved'
p2927
aS'recombinant HBcAg particles'
p2928
aS'given 15 minutes'
p2929
aS'trial Nine participants'
p2930
aS'immunomodulatory effect'
p2931
aS'were healthy'
p2932
aS'reported nasal'
p2933
aS'get 25 seroprotection'
p2934
aS'vaccine Heberbiovac'
p2935
aS'Local adverse'
p2936
aS'graded as severe'
p2937
aS'formulation Sterile'
p2938
aS'recipients one'
p2939
aS'emitted fluorescence'
p2940
aS'authors'
p2941
aS'basal surface'
p2942
aS'aches decreased appetite'
p2943
aS'All sera were'
p2944
aS'attention Serious'
p2945
aS'samples were evaluated'
p2946
aS'candidate administered'
p2947
aS'balanced format'
p2948
aS'other commercial anti'
p2949
aS'impact'
p2950
aS'purity superior'
p2951
aS'parameters'
p2952
aS'64 8IU'
p2953
aS'severe symptoms'
p2954
aS'until use'
p2955
aS'any other nasal'
p2956
aS'basic hematological parameters'
p2957
aS'minutes apart All'
p2958
aS'HBs 10IU'
p2959
aS'prior inoculation'
p2960
aS'surface through'
p2961
aS'Thirty'
p2962
aS'immunogenicity of full'
p2963
aS'antigens by nasal'
p2964
aS'Geometric mean'
p2965
aS'event profile'
p2966
aS'assigned arbitrarily'
p2967
aS'instructed to measure'
p2968
aS'human sera'
p2969
aS'closely'
p2970
aS'male adults between'
p2971
aS'were considered hyper'
p2972
aS'anti HBs protective'
p2973
aS'candidate containing'
p2974
aS'evaluated during'
p2975
aS'State Center'
p2976
aS'HBsAg titer Anti'
p2977
aS'only 30'
p2978
aS'HBs ELISA'
p2979
aS'common'
p2980
aS'rhinorrhea nasal'
p2981
aS'administration also'
p2982
aS'subjects reporting adverse'
p2983
aS'residence time'
p2984
aS'both cases'
p2985
aS'vaccines plant derived'
p2986
aS'plasmid containing'
p2987
aS'Enrique'
p2988
aS'very encouraging taking'
p2989
aS'severe Clinically significant'
p2990
aS'nasal bleeding Solicited'
p2991
aS'Neither'
p2992
aS'trial Nine'
p2993
aS'allowed expiration'
p2994
aS'nasal ulceration'
p2995
aS'97 of adverse'
p2996
aS'kits Samples'
p2997
aS'immunization sera'
p2998
aS'77 recorded'
p2999
aS'currently'
p3000
aS'diluted'
p3001
aS'event There'
p3002
aS'immediate adverse'
p3003
aS'g Miacalcin'
p3004
aS'tolerated safe'
p3005
aS'DC Additionally'
p3006
aS'neither clinical'
p3007
aS'outcomes were'
p3008
aS'corroborates previous findings'
p3009
aS'obtaining written'
p3010
aS'products or immunoglobulin'
p3011
aS'other well'
p3012
aS'study entry'
p3013
aS'8IU l All'
p3014
aS'after vaccine administration'
p3015
aS'nostril were'
p3016
aS'sera Only'
p3017
aS'itching anosmia'
p3018
aS'2000 Among'
p3019
aS'peripheral blood'
p3020
aS'were kept'
p3021
aS'HBV specific immune'
p3022
aS'nucleoprotein in trace'
p3023
aS'headache muscle'
p3024
aS'antibody levels 100IU'
p3025
aS'HBs in sera'
p3026
aS'novel hepatitis'
p3027
aS'immunotherapy'
p3028
aS'became'
p3029
aS'severity Binomial'
p3030
aS'80 90'
p3031
aS'toxicology'
p3032
aS'event rate'
p3033
aS'study products'
p3034
aS'arbitrarily'
p3035
aS'point'
p3036
aS'order to increase'
p3037
aS'protective anti'
p3038
aS'congestion'
p3039
aS'recorded during 90'
p3040
aS'patient with high'
p3041
aS'were reported during'
p3042
aS'populations known'
p3043
aS'high mucosal nasal'
p3044
aS'antibody against'
p3045
aS'multi specific helper'
p3046
aS'vessel'
p3047
aS'candidate formulated'
p3048
aS'rabbits with induction'
p3049
aS'6 months'
p3050
aS'participants received'
p3051
aS'between 24h'
p3052
aS'venipuncture for measurement'
p3053
aS'doctor s visits'
p3054
aS'height between vaccine'
p3055
aS'strategy'
p3056
aS'reduction'
p3057
aS'ensured'
p3058
aS'All anti HBs'
p3059
aS'vaccine recipients according'
p3060
aS'detection of cellular'
p3061
aS'allows interaction'
p3062
aS'annoying'
p3063
aS'abnormalities in clinical'
p3064
aS'one hyper responder'
p3065
aS'trained physician'
p3066
aS'both antigens'
p3067
aS'study in 19'
p3068
aS'Sterile physiologic saline'
p3069
aS'occurred during'
p3070
aS'acemannan Whether'
p3071
aS'liver'
p3072
aS'titers of more'
p3073
aS'Preclinical toxicological'
p3074
aS'developments'
p3075
aS'screening visit'
p3076
aS'highest'
p3077
aS'cause'
p3078
aS'resulting'
p3079
aS'solid'
p3080
aS'safe and immunogenic'
p3081
aS'enrollment'
p3082
aS'coated with commercial'
p3083
aS'well known'
p3084
aS'vaccine allocation'
p3085
aS'antibody tests against'
p3086
aS'behavior'
p3087
aS'Exposure'
p3088
aS'resolving within 72h'
p3089
aS'Becton Dickinson were'
p3090
aS'Furthermore local'
p3091
aS'nurse sprayed'
p3092
aS'37'
p3093
aS'subjects signed'
p3094
aS'volunteers were aware'
p3095
aS'binding'
p3096
aS'study after'
p3097
aS'production facilities'
p3098
aS'display strong'
p3099
aS'immunomodulatory'
p3100
aS'during 90'
p3101
aS'commonly'
p3102
aS'recipients achieved anti'
p3103
aS'seroprotected vaccine'
p3104
aS'reach 75'
p3105
aS'alone'
p3106
aS'aches'
p3107
aS'rate increased'
p3108
aS'estimate'
p3109
aS'reporting of adverse'
p3110
aS'fashion on code'
p3111
aS'studies were'
p3112
aS'authors thank'
p3113
aS'nausea vomiting diarrhea'
p3114
aS'weak HBV specific'
p3115
aS'negative result'
p3116
aS'conflict'
p3117
aS'influenza nasal'
p3118
aS'g HBsAg mixed'
p3119
aS'7 of them'
p3120
aS'performed periodical examinations'
p3121
aS'Miacalcin'
p3122
aS'nasally parenteral administered'
p3123
aS'48hours on administration'
p3124
aS'conducted in Sprague'
p3125
aS'antibody titers against'
p3126
aS'mild self limiting'
p3127
aS'severe Severe reactions'
p3128
aS'systemic reactions 71'
p3129
aS'HBcAg Individuals were'
p3130
aS'did not increase'
p3131
aS'older'
p3132
aS'percentages'
p3133
aS'negative for HBsAg'
p3134
aS'responder volunteer'
p3135
aS'sera Briefly UMELISA'
p3136
aS'clinically significant'
p3137
aS'achieved antibody'
p3138
aS'polyclonal'
p3139
aS'anti HBs 100IU'
p3140
aS'negative immunomodulatory'
p3141
aS'entry'
p3142
aS'clearance'
p3143
aS'Quality'
p3144
aS'adverse events 58'
p3145
aS'carrier state'
p3146
aS'nucleoprotein'
p3147
aS'test for proportions'
p3148
aS'CECMED'
p3149
aS'administered using'
p3150
aS'given 15'
p3151
aS'sera were available'
p3152
aS'devices and methodologies'
p3153
aS'competitive'
p3154
aS'cells transport antigens'
p3155
aS'administration enables antigens'
p3156
aS'against HBsAg 10IU'
p3157
aS'rate exceeded'
p3158
aS'useful'
p3159
aS'recombinant HBsAg subtype'
p3160
aS'Written informed'
p3161
aS'immunoenzymatic assay'
p3162
aS'HBs ELISA kits'
p3163
aS'nasal route showing'
p3164
aS'schedule Following'
p3165
aS'corroborates'
p3166
aS'added reacting'
p3167
aS'specific immune response'
p3168
aS'g of HBcAg'
p3169
aS'12h post immunization'
p3170
aS'estimate each'
p3171
aS'same volume'
p3172
aS'immediate adverse events'
p3173
aS'increase in frequency'
p3174
aS'transparent liquid'
p3175
aS'doses Local adverse'
p3176
aS'liver failure'
p3177
aS'format'
p3178
aS'situation'
p3179
aS'included fever chills'
p3180
aS'HBcAg nucleic acids'
p3181
aS'support further'
p3182
aS'Finlay Hospital Havana'
p3183
aS'showing antibody'
p3184
aS'purified recombinant full'
p3185
aS'0 05'
p3186
aS'allocated to placebo'
p3187
aS'13 excess over'
p3188
aS'diseases immunosuppressive'
p3189
aS'reacting'
p3190
aS'adjustments were made'
p3191
aS'respect to anti'
p3192
aS'signal'
p3193
aS'hospitalizations were also'
p3194
aS'only comprises'
p3195
aS'reported in recipients'
p3196
aS'developed anti'
p3197
aS'over nasally parenteral'
p3198
aS'primary APCs'
p3199
aS'allocation All aspects'
p3200
aS'conducted to characterize'
p3201
aS'Serious adverse'
p3202
aS'low responders'
p3203
aS'nausea vomiting'
p3204
aS'Dawley'
p3205
aS'steroid anti'
p3206
aS'controlled double blinded'
p3207
aS'normal functioning may'
p3208
aS'neutralization using'
p3209
aS'delivered'
p3210
aS'reconstituted'
p3211
aS'rates of seroprotection'
p3212
aS'incubated with samples'
p3213
aS'interest to declare'
p3214
aS'fatal or life'
p3215
aS'nasal bleeding'
p3216
aS'particle to more'
p3217
aS'derived vaccines'
p3218
aS'immunization Withdrawal'
p3219
aS'any immediate'
p3220
aS'nose'
p3221
aS'hyper responder volunteer'
p3222
aS'patient'
p3223
aS'fifth vaccine dose'
p3224
aS'dose at time'
p3225
aS'matched pre'
p3226
aS'treatment display strong'
p3227
aS'vaccine and placebo'
p3228
aS'Dickinson Depending'
p3229
aS'helper and cytotoxic'
p3230
aS'reasonably immunogenic'
p3231
aS'Chronic HBV'
p3232
aS'hepatitis B surface'
p3233
aS'saliva from one'
p3234
aS'body system Adverse'
p3235
aS'after inoculation'
p3236
aS'apparent abnormalities'
p3237
aS'range'
p3238
aS'male adult'
p3239
aS'4 C until'
p3240
aS'remaining 19'
p3241
aS'successive vaccine'
p3242
aS'immunization for any'
p3243
aS'comparison licensed HBV'
p3244
aS'annoying may'
p3245
aS'anti HBs 10IU'
p3246
aS'assay for qualitative'
p3247
aS'candidate developed'
p3248
aS'formal sample'
p3249
aS'antigen uptake'
p3250
aS'Only two moderate'
p3251
aS'recent exposure'
p3252
aS'all participants prior'
p3253
aS'reactions 71'
p3254
aS'enhancement of antiviral'
p3255
aS'computer'
p3256
aS'luminal'
p3257
aS'long'
p3258
aS'after obtaining'
p3259
aS'hepatocellular carcinoma'
p3260
aS'there were'
p3261
aS'time 37'
p3262
aS'result On completion'
p3263
aS'general reaction category'
p3264
aS'self limited'
p3265
aS'two moderate'
p3266
aS'nor induced'
p3267
aS'virus after'
p3268
aS'registered'
p3269
aS'19 participants were'
p3270
aS'X02763 HBsAg'
p3271
aS'Severe'
p3272
aS'calcitonin salmon'
p3273
aS'injection'
p3274
aS'HBs only'
p3275
aS'further immunogenicity'
p3276
aS'group Sneezing palate'
p3277
aS'such as older'
p3278
aS'commonly reported nasal'
p3279
aS'Heberbiovac HB CIGB'
p3280
aS'seroconversion after'
p3281
aS'given via'
p3282
aS'co administered HBsAg'
p3283
aS'criterion for protection'
p3284
aS'increased to 75'
p3285
aS'associated'
p3286
aS'Local site reactions'
p3287
aS'minutes'
p3288
aS'administration of each'
p3289
aS'participants were randomly'
p3290
aS'4 pre existing'
p3291
aS'continuous variables Adverse'
p3292
aS'quantification'
p3293
aS'generated list'
p3294
aS'second vaccine'
p3295
aS'immunosorbent assay ELISA'
p3296
aS'microscopy EM analysis'
p3297
aS'mouse studies'
p3298
aS'carcinoma'
p3299
aS'e g Miacalcin'
p3300
aS'amounts'
p3301
aS'screen failures'
p3302
aS'studied dose'
p3303
aS'over systemic'
p3304
aS'transport'
p3305
aS'visits and hospitalizations'
p3306
aS'gratefully acknowledge'
p3307
aS'HBcAg Individuals'
p3308
aS'fourth immunization Withdrawal'
p3309
aS'positive response'
p3310
aS'most commonly'
p3311
aS'15 participants'
p3312
aS'activity of HBcAg'
p3313
aS'tests 4 pre'
p3314
aS'generated'
p3315
aS'secondary outcomes'
p3316
aS'resulting HBcAg had'
p3317
aS'further assays'
p3318
aS'nucleic acids bound'
p3319
aS'Participants were'
p3320
aS'immunogenic in healthy'
p3321
aS'samples All anti'
p3322
aS'mucosal immune system'
p3323
aS'methodologies'
p3324
aS'fluorescence'
p3325
aS'volumes of samples'
p3326
aS'placebo solution All'
p3327
aS'network of approximately'
p3328
aS'high HBsAg titer'
p3329
aS'recorded adverse events'
p3330
aS'group No unexpected'
p3331
aS'HBs only 30'
p3332
aS'study personnel'
p3333
aS'international'
p3334
aS'developed seroprotective'
p3335
aS'having'
p3336
aS'time of immunization'
p3337
aS'code'
p3338
aS'partial'
p3339
aS'resolving acute'
p3340
aS'group remained positive'
p3341
aS's head'
p3342
aS'existing'
p3343
aS'fourth dose'
p3344
aS'Immunoassay'
p3345
aS'Biotechnology Havana'
p3346
aS'were not substantially'
p3347
aS'third dose'
p3348
aS'mild symptom'
p3349
aS'consultations or doctor'
p3350
aS'mild moderate'
p3351
aS'l per nostril'
p3352
aS'resolving within'
p3353
aS'young'
p3354
aS'between study'
p3355
aS'chronic infection resolving'
p3356
aS'excluded'
p3357
aS'fatal'
p3358
aS'One recipient'
p3359
aS'remained positive'
p3360
aS'adjuvants gene vaccine'
p3361
aS'HBV vaccine Heberbiovac'
p3362
aS'random'
p3363
aS'most frequent'
p3364
aS'group 59'
p3365
aS'vaccine allocation All'
p3366
aS'25 seroprotection'
p3367
aS'venipuncture'
p3368
aS'HBs 10 100IU'
p3369
aS'state of unresponsiveness'
p3370
aS'vaccine and were'
p3371
aS'mucosal immunization further'
p3372
aS'electron'
p3373
aS'cellular'
p3374
aS'functional defects'
p3375
aS'young adults 30'
p3376
aS'cell and cytotoxic'
p3377
aS'100IU l Sera'
p3378
aS'nausea'
p3379
aS'recombinant Heberbiovac HB'
p3380
aS'entire'
p3381
aS'core HBc specific'
p3382
aS'dose of HBsAg'
p3383
aS'induced local damage'
p3384
aS'peripheral blood mononuclear'
p3385
aS'HBsAg subtype CIGB'
p3386
aS'race'
p3387
aS'7 years'
p3388
aS'Adverse events did'
p3389
aS'levels 100IU'
p3390
aS'concluded'
p3391
aS'CIGB production facilities'
p3392
aS'number X02763 HBsAg'
p3393
aS'events as well'
p3394
aS'length recombinant'
p3395
aS'bleeding'
p3396
aS'distressing interference'
p3397
aS'kept under observation'
p3398
aS'responder volunteer generating'
p3399
aS'State'
p3400
aS'included persistently abnormal'
p3401
aS'study No cases'
p3402
aS'surface network'
p3403
aS'transformed previously'
p3404
aS'group sample'
p3405
aS'limiting resolving within'
p3406
aS'anti HBV'
p3407
aS'cutaneous'
p3408
aS'clinical data'
p3409
aS'post immunization Solicited'
p3410
aS'were similar'
p3411
aS'HBV specific'
p3412
aS'consistently'
p3413
aS'code labeled matched'
p3414
aS'white race'
p3415
aS'values'
p3416
aS'hematology values were'
p3417
aS'stuffiness or congestion'
p3418
aS'thin'
p3419
aS'body'
p3420
aS'developed seroprotective antibody'
p3421
aS'doses Adverse'
p3422
aS'status after'
p3423
aS'years range 18'
p3424
aS'other particulate antigens'
p3425
aS'volunteers inoculated'
p3426
aS'strain W3110'
p3427
aS'other symptoms'
p3428
aS'different than'
p3429
aS'functioning may'
p3430
aS'size nine participants'
p3431
aS'vaccine administration'
p3432
aS'consideration'
p3433
aS'any study procedure'
p3434
aS'Participants were kept'
p3435
aS'compromised'
p3436
aS'39'
p3437
aS'38'
p3438
aS'PBMCs'
p3439
aS'involved'
p3440
aS'distribution point'
p3441
aS'fully demonstrated'
p3442
aS'total serum'
p3443
aS'volume of 125'
p3444
aS'vaccines or had'
p3445
aS'vial contained'
p3446
aS'healthy young'
p3447
aS'anti HBs equal'
p3448
aS'examinations'
p3449
aS'formulated'
p3450
aS'all other reactions'
p3451
aS'fluorescent substrate'
p3452
aS'molecule as revealed'
p3453
aS'titer Anti HBs'
p3454
aS'outcomes'
p3455
aS'HBsAg immunogenicity Preclinical'
p3456
aS'comparison with other'
p3457
aS'unresponsiveness'
p3458
aS'sensitivity to any'
p3459
aS'4 pre'
p3460
aS'plant derived'
p3461
aS'each treatment group'
p3462
aS'acute or chronic'
p3463
aS'neither irritating'
p3464
aS'results of preclinical'
p3465
aS'inoculation adverse reactions'
p3466
aS'severe Severe'
p3467
aS'anti inflammatory'
p3468
aS'chemistry and basic'
p3469
aS'duplicate'
p3470
aS'examination'
p3471
aS'days post immunization'
p3472
aS'secondary outcomes were'
p3473
aS'HBcAg CIGB Havana'
p3474
aS'anti inflammatory analgesics'
p3475
aS'first inoculation using'
p3476
aS'10 100IU'
p3477
aS'computer generated'
p3478
aS'Miacalcin nasal'
p3479
aS'occurred'
p3480
aS'transient'
p3481
aS'history of sensitivity'
p3482
aS'rabbit'
p3483
aS'vaccine candidate formulated'
p3484
aS'local reaction'
p3485
aS'nasal conditions'
p3486
aS'randomized and received'
p3487
aS'evident and corroborates'
p3488
aS'animals'
p3489
aS'known nasally'
p3490
aS'immunodominant'
p3491
aS'until use Nasal'
p3492
aS'subtype CIGB'
p3493
aS'Solid phase antigen'
p3494
aS'were closely assessed'
p3495
aS'mucosal blood'
p3496
aS'field'
p3497
aS'positive for anti'
p3498
aS'profile Recent advances'
p3499
aS'Miacalcin nasal spray'
p3500
aS'pre study'
p3501
aS'study drug'
p3502
aS'administered through novel'
p3503
aS'calculation'
p3504
aS'adults and 80'
p3505
aS'proportions'
p3506
aS'symptom present'
p3507
aS'Written'
p3508
aS'anosmia nasal ulceration'
p3509
aS'mononuclear cells PBMCs'
p3510
aS'samples Solid phase'
p3511
aS'particles'
p3512
aS'similar proportion hypo'
p3513
aS'0 2IU'
p3514
aS'doses Adverse events'
p3515
aS'irritating potential'
p3516
aS'during 90 applied'
p3517
aS'vessel status'
p3518
aS'dependent'
p3519
aS'90 day'
p3520
aS'adapted'
p3521
aS'candidate showed'
p3522
aS'using similar'
p3523
aS'hypothesis testing'
p3524
aS'also collected'
p3525
aS'developed anti HBs'
p3526
aS'6ml'
p3527
aS'any local reaction'
p3528
aS'43 subjects'
p3529
aS'discomfort'
p3530
aS'limiting and disappeared'
p3531
aS'without adjuvants'
p3532
aS'any immediate adverse'
p3533
aS'Furthermore participants were'
p3534
aS'recipients as early'
p3535
aS'vaccine doses Adverse'
p3536
aS'binding of HBsAg'
p3537
aS'mice and rabbits'
p3538
aS'study were'
p3539
aS'even without adjuvants'
p3540
aS'One'
p3541
aS'Furthermore participants'
p3542
aS'Nasal administration enables'
p3543
aS'study clearly demonstrates'
p3544
aS'adjustments were'
p3545
aS'competitive sequential'
p3546
aS'Local adverse events'
p3547
aS'abnormalities visualized'
p3548
aS'significant events were'
p3549
aS'preclinical'
p3550
aS'produced'
p3551
aS'including'
p3552
aS'units per liter'
p3553
aS'All reactions were'
p3554
aS'administered by intranasal'
p3555
aS'chemistry'
p3556
aS'white race predominated'
p3557
aS'superior'
p3558
aS'mice with full'
p3559
aS'absent mild symptom'
p3560
aS'consent Individuals'
p3561
aS'reactions combined'
p3562
aS'each rate'
p3563
aS'were self'
p3564
aS'70IU'
p3565
aS'antigen sampling'
p3566
aS'specific active'
p3567
aS'g purified recombinant'
p3568
aS'accession number'
p3569
aS'physicians'
p3570
aS'study nurse sprayed'
p3571
aS'mechanisms'
p3572
aS'assessed by Fisher'
p3573
aS'prophylactic vaccines plant'
p3574
aS'Binomial distribution'
p3575
aS'Solid'
p3576
aS'years range'
p3577
aS'consent and underwent'
p3578
aS'symptom bothersome discomfort'
p3579
aS'functional'
p3580
aS'licensed nasal flu'
p3581
aS'interference with usual'
p3582
aS'two 25'
p3583
aS'study group remained'
p3584
aS'documented'
p3585
aS'high HBsAg'
p3586
aS'predominated over systemic'
p3587
aS'specific active immunotherapy'
p3588
aS'vaccine antigens NASVAC'
p3589
aS'adverse event There'
p3590
aS'route of immunization'
p3591
aS'participants during'
p3592
aS'epistaxis were'
p3593
aS'Biokit Barcelona'
p3594
aS'systemic adverse effects'
p3595
aS'induced serum'
p3596
aS'after immunization'
p3597
aS'determine mucosal irritating'
p3598
aS'blood vessel'
p3599
aS'any adjuvant'
p3600
aS'estimates and 95'
p3601
aS'clinically significant acute'
p3602
aS'core HBc'
p3603
aS'Thirty days'
p3604
aS'cell responses'
p3605
aS'profile under routine'
p3606
aS'Cuba licensed'
p3607
aS'inoculation adverse'
p3608
aS'exceeded'
p3609
aS'80'
p3610
aS'first dose'
p3611
aS'access Furthermore local'
p3612
aS'were given via'
p3613
aS'self limited HBV'
p3614
aS'rez'
p3615
aS'older individuals renal'
p3616
aS'clinical chemistry'
p3617
aS'other well known'
p3618
aS'l seroprotection percentage'
p3619
aS'controlled double'
p3620
aS'include'
p3621
aS'third vaccine dose'
p3622
aS'confirmed in further'
p3623
aS'medical attention Serious'
p3624
aS'formulation and placebo'
p3625
aS'first inoculation Blood'
p3626
aS'solid phase'
p3627
aS'reacts'
p3628
aS'HBV chronically'
p3629
aS'nasal spray device'
p3630
aS'intranasal route'
p3631
aS'serum antibody responses'
p3632
aS'group observation'
p3633
aS'performed however each'
p3634
aS'study procedure'
p3635
aS'70IU l One'
p3636
aS'mean age'
p3637
aS'candidate tested'
p3638
aS'backwards'
p3639
aS'mucosal immune'
p3640
aS'Sprague Dawley rats'
p3641
aS'after obtaining written'
p3642
aS'against HBV infection'
p3643
aS'HBs antibodies'
p3644
aS'e g influenza'
p3645
aS'event There were'
p3646
aS'chills'
p3647
aS'total anti HBc'
p3648
aS'were needed'
p3649
aS'plates 10'
p3650
aS'length HBcAg CIGB'
p3651
aS'sera block antigenic'
p3652
aS'rabbit anti'
p3653
aS'Administration'
p3654
aS'showed seroconversion against'
p3655
aS'spray devices Accuspray'
p3656
aS'58'
p3657
aS'planned medical'
p3658
aS'C terminal region'
p3659
aS'vaccine only comprises'
p3660
aS'mucosal nasal immunogenicity'
p3661
aS'reporting specific'
p3662
aS'promoter'
p3663
aS'antigenicity'
p3664
aS'reactions were defined'
p3665
aS'immunization Solicited adverse'
p3666
aS'systemic immunity elicited'
p3667
aS'discomfort enough'
p3668
aS'adult volunteers'
p3669
aS'antigens to access'
p3670
aS'analgesics non planned'
p3671
aS'0 0038'
p3672
aS'after vaccine'
p3673
aS'report in humans'
p3674
aS'pre existing'
p3675
aS'HBcAg to HBsAg'
p3676
aS'Volunteers were recruited'
p3677
aS'day period'
p3678
aS'1 hour after'
p3679
aS'limitations explained'
p3680
aS'inoculation Adverse events'
p3681
aS'flu vaccine using'
p3682
aS'Novartis'
p3683
aS'placebo developed antibodies'
p3684
aS'obtained by venipuncture'
p3685
aS'screening regarding'
p3686
aS'institution'
p3687
aS'independent antigen'
p3688
aS'blinded study'
p3689
aS'observed'
p3690
aS'vaccine studies HBcAg'
p3691
aS'nasal HBsAg'
p3692
aS'HBcAg nasal vaccine'
p3693
aS'size nine'
p3694
aS'obtained from all'
p3695
aS'any component'
p3696
aS'assays'
p3697
aS'consent Individuals were'
p3698
aS'each subject'
p3699
aS'calcitonin'
p3700
aS'salmon Novartis'
p3701
aS'elicit seroconversion'
p3702
aS'sera Only anti'
p3703
aS'distribution point estimates'
p3704
aS'cells transport'
p3705
aS'phase II'
p3706
aS'clinical studies'
p3707
aS'cytoplasm'
p3708
aS'them were requested'
p3709
aS'apart All'
p3710
aS'5 More'
p3711
aS'protective anti HBs'
p3712
aS'prevent permanent'
p3713
aS'derived vaccines vaccines'
p3714
aS'events included anterior'
p3715
aS'22nm'
p3716
aS'standard parenteral'
p3717
aS'first in human'
p3718
aS'headache both'
p3719
aS'HBcAg nucleic'
p3720
aS'HBcAg combined formulations'
p3721
aS'After'
p3722
aS'titers around 70IU'
p3723
aS'Center Havana Cuba'
p3724
aS'M cell pockets'
p3725
aS'well as hypo'
p3726
aS'chronic diseases'
p3727
aS'candidate were undertaken'
p3728
aS'unresponsiveness characteristic'
p3729
aS'were not available'
p3730
aS'worldwide'
p3731
aS'II clinical'
p3732
aS'injection and up'
p3733
aS'provided to participants'
p3734
aS'II studies'
p3735
aS'dose to achieve'
p3736
aS'inflammatory Th1 response'
p3737
aS'conditions occurred'
p3738
aS'antigens with DC'
p3739
aS'digestive'
p3740
aS'eight'
p3741
aS'posterior nasal dripping'
p3742
aS'nuisance'
p3743
aS'total dose'
p3744
aS'treatment group observation'
p3745
aS'HBsAg exploiting'
p3746
aS'events were tabulated'
p3747
aS'100 of vaccine'
p3748
aS'chronic patients'
p3749
aS'consequences'
p3750
aS'95 purity'
p3751
aS'further phase'
p3752
aS'schedule formulation'
p3753
aS'modulatory effect'
p3754
aS'headache both reports'
p3755
aS'hour after vaccine'
p3756
aS'immunotherapy in HBV'
p3757
aS'available for screening'
p3758
aS'125l per nostril'
p3759
aS'findings'
p3760
aS'comparison licensed'
p3761
aS'0038'
p3762
aS'developments to boost'
p3763
aS'local adverse event'
p3764
aS'negative immunomodulatory effect'
p3765
aS'immunopotentiating'
p3766
aS'participants completed'
p3767
aS'visualized'
p3768
aS'examinations with visualization'
p3769
aS'considered hyper'
p3770
aS'year 2000'
p3771
aS'Briefly anti'
p3772
aS'fourth immunization'
p3773
aS'placebo group Sneezing'
p3774
aS'Organization there'
p3775
aS'pre study screening'
p3776
aS'events between study'
p3777
aS'tolerance All'
p3778
aS'reporting of nasal'
p3779
aS'rash'
p3780
aS'including antigen uptake'
p3781
aS'under routine'
p3782
aS'most moderate symptom'
p3783
aS'vaccine such'
p3784
aS'achieve'
p3785
aS'approximately 500DC mm'
p3786
aS'C until use'
p3787
aS'center randomized placebo'
p3788
aS'peptide'
p3789
aS'28nm'
p3790
aS'g nasal'
p3791
aS'Whether'
p3792
aS'adults in order'
p3793
aS'disappeared within 72hours'
p3794
aS'severe symptoms very'
p3795
aS'were reported more'
p3796
aS'sterile phosphate buffer'
p3797
aS'had clinically significant'
p3798
aS'patients and immune'
p3799
aS'samples Solid'
p3800
aS'vaccine formulation consisting'
p3801
aS'antibody tests'
p3802
aS'given via nasal'
p3803
aS'anti HBc alkaline'
p3804
aS'baseline all'
p3805
aS'strong polyclonal'
p3806
aS'approach'
p3807
aS'assay ELISA'
p3808
aS'exceeded 15'
p3809
aS'samples were collected'
p3810
aS'hyper responder 100IU'
p3811
aS'phosphatase conjugate'
p3812
aS'potent immunogen even'
p3813
aS'fixed'
p3814
aS'site reactions were'
p3815
aS'e g nasal'
p3816
aS'derived recombinant HBsAg'
p3817
aS'study support'
p3818
aS'screening regarding chemical'
p3819
aS'acceptable local'
p3820
aS'humans'
p3821
aS'trace amounts'
p3822
aS'other reactions combined'
p3823
aS'HBsAg in mice'
p3824
aS'clinical adverse'
p3825
aS'display strong polyclonal'
p3826
aS'carriers of hepatitis'
p3827
aS'HBsAg significantly increases'
p3828
aS'sample size calculation'
p3829
aS'B cell'
p3830
aS'days All'
p3831
aS'digestive tract'
p3832
aS'HBV chronic'
p3833
aS'included anterior'
p3834
aS'cytokine response'
p3835
aS'HBs protective'
p3836
aS'investigators'
p3837
aS'any other symptoms'
p3838
aS'routine'
p3839
aS'were measured'
p3840
aS'cells to work'
p3841
aS'bothersome discomfort enough'
p3842
aS'recombinant hepatitis'
p3843
aS'dendritic cell populations'
p3844
aS'electron microscopy'
p3845
aS'size calculation'
p3846
aS'local reaction category'
p3847
aS'emitted'
p3848
aS'disorders or medication'
p3849
aS'immunization nor'
p3850
aS'single nasal'
p3851
aS'anti HBs alkaline'
p3852
aS'hypothesis'
p3853
aS'failure and hepatocellular'
p3854
aS'successive vaccine doses'
p3855
aS'responses against both'
p3856
aS'had no history'
p3857
aS'Also chronic HBV'
p3858
aS'phase II studies'
p3859
aS'nuisance at most'
p3860
aS'Individuals of white'
p3861
aS'parenteral HBV vaccine'
p3862
aS'taking'
p3863
aS'acknowledge'
p3864
aS'both reports'
p3865
aS'EM analysis Further'
p3866
aS'responder 100IU'
p3867
aS'anti HBs UMELISA'
p3868
aS'itching anosmia nasal'
p3869
aS'HBsAg or HBcAg'
p3870
aS'otorhinolaryngologist performed'
p3871
aS'site reactions'
p3872
aS'5 of seroprotected'
p3873
aS'Toxicology and Carlos'
p3874
aS'were estimated'
p3875
aS'animal studies'
p3876
aS'17 and inability'
p3877
aS'candidate demonstrated seroconversion'
p3878
aS'adverse events within'
p3879
aS'include combined prophylactic'
p3880
aS'posterior dripping'
p3881
aS'fact along'
p3882
aS'study clearly'
p3883
aS'Finally'
p3884
aS'administration enables'
p3885
aS'adults Local site'
p3886
aS'seroprotection percentage anti'
p3887
aS'immunity Nasal'
p3888
aS'human clinical trial'
p3889
aS'rates of local'
p3890
aS'methods Concurrent'
p3891
aS'trial were closely'
p3892
aS'one hyper'
p3893
aS'mucosal irritating'
p3894
aS'sequential immunoenzymatic'
p3895
aS'statistical analysis There'
p3896
aS'activator enabling activated'
p3897
aS'years There were'
p3898
aS'kept under'
p3899
aS'3 and epistaxis'
p3900
aS'days following'
p3901
aS'Research Ethics'
p3902
aS'monoclonal'
p3903
aS'muscle aches'
p3904
aS'dripping nasal'
p3905
aS'Drug Quality'
p3906
aS'detection of IgA'
p3907
aS'comprising HBsAg'
p3908
aS'successive reaction'
p3909
aS'sponsor institution Five'
p3910
aS'headache muscle aches'
p3911
aS'decreased'
p3912
aS'labeled matched'
p3913
aS'one month after'
p3914
aS'acute hepatitis'
p3915
aS'virus anti HBs'
p3916
aS'adverse events between'
p3917
aS'secretion of HBeAg'
p3918
aS'multi'
p3919
aS'hepatocellular'
p3920
aS'8 of vaccine'
p3921
aS'reported among individuals'
p3922
aS'statistical analysis'
p3923
aS'spray devices'
p3924
aS'other nasal drug'
p3925
aS'expiration'
p3926
aS'attention or severe'
p3927
aS'preliminary immunogenicity'
p3928
aS'systemic reactions'
p3929
aS'five vaccine doses'
p3930
aS'helper'
p3931
aS'Cuba and 50'
p3932
aS'inoculation using'
p3933
aS'cutaneous rash'
p3934
aS'completed'
p3935
aS'90 applied'
p3936
aS'mucosal adjuvant'
p3937
aS'specific immune'
p3938
aS'interference with normal'
p3939
aS'visualized in vaccine'
p3940
aS'symptoms very distressing'
p3941
aS'dual'
p3942
aS'random numbers'
p3943
aS'Rates of adverse'
p3944
aS'day 30 Thirty'
p3945
aS'Geometric'
p3946
aS'compartment protected'
p3947
aS'prior to any'
p3948
aS'blood screening'
p3949
aS'recording of adverse'
p3950
aS'supported'
p3951
aS'severe Local'
p3952
aS'infrequent Adverse'
p3953
aS'were given 15'
p3954
aS'abnormal baseline'
p3955
aS'units'
p3956
aS'formulations in healthy'
p3957
aS'further phase II'
p3958
aS'group No subjects'
p3959
aS'adults 30 days'
p3960
aS'antibody level'
p3961
aS'around 70IU'
p3962
aS'85 5 More'
p3963
aS'S protein'
p3964
aS'tolerated and reasonably'
p3965
aS'29 7 years'
p3966
aS'revealed neither clinical'
p3967
aS'placebo solution'
p3968
aS'administration of HBcAg'
p3969
aS'sera block'
p3970
aS'reactions were combined'
p3971
aS'international units'
p3972
aS'formulation in each'
p3973
aS'administration comprising'
p3974
aS'center'
p3975
aS'difficult to access'
p3976
aS'fully'
p3977
aS'Conversely'
p3978
aS'were tabulated'
p3979
aS'24h and 72h'
p3980
aS'failures'
p3981
aS'Chronic HBV infection'
p3982
aS'personnel'
p3983
aS'comparisons'
p3984
aS'muscle'
p3985
aS'applied doses 85'
p3986
aS'usual'
p3987
aS'subjects reporting specific'
p3988
aS'Baseline'
p3989
aS'77 adverse events'
p3990
aS'HBsAg HBcAg combined'
p3991
aS'Immunoassay Center Havana'
p3992
aS'recipients of other'
p3993
aS'subjects withdrew'
p3994
aS'salmon'
p3995
aS'HBcAg at day'
p3996
aS'were no differences'
p3997
aS'secreted protein'
p3998
aS'impaired'
p3999
aS'Barcelona Spain'
p4000
aS'inoculations'
p4001
aS'group observation period'
p4002
aS'variables Adverse'
p4003
aS'other licensed nasal'
p4004
aS'devices Accuspray Becton'
p4005
aS'achieved anti'
p4006
aS'10 of adults'
p4007
aS'immunoenhancing activity'
p4008
aS'were considered'
p4009
aS'values were found'
p4010
aS'transparent'
p4011
aS'antiviral therapies'
p4012
aS'reasons'
p4013
aS'potent B cell'
p4014
aS'l One'
p4015
aS'Despite'
p4016
aS'lymphocytes'
p4017
aS'severe Clinically'
p4018
aS'matched'
p4019
aS'decreased appetite nausea'
p4020
aS'inoculation and were'
p4021
aS'closely assessed'
p4022
aS'increased'
p4023
aS'tolerated and induced'
p4024
aS'immunization with hepatitis'
p4025
aS'mild self'
p4026
aS'were aware'
p4027
aS'9 sterile saline'
p4028
aS'increases'
p4029
aS'Food'
p4030
aS'recipients achieved'
p4031
aS'UMELISA plates'
p4032
aS'values were'
p4033
aS'each immunization'
p4034
aS'Further antigenicity'
p4035
aS'three doses'
p4036
aS'significant no adjustments'
p4037
aS'Sneezing palate'
p4038
aS'most moderate'
p4039
aS'mucosal immunogenicity'
p4040
aS'HB CIGB Havana'
p4041
aS'exploiting'
p4042
aS'qualitative'
p4043
aS'considered statistically'
p4044
aS'differences between vaccine'
p4045
aS'hosts'
p4046
aS'l per well'
p4047
aS'days post'
p4048
aS'infection In vaccine'
p4049
aS'Preclinical mouse'
p4050
aS'clearly evident'
p4051
aS'therapeutic'
p4052
aS'products were stored'
p4053
aS'significant persistent'
p4054
aS'hospitalizations'
p4055
aS'placebo received'
p4056
aS'underwent'
p4057
aS'schedule In two'
p4058
aS'balanced format using'
p4059
aS'baseline biochemistry'
p4060
aS'events were mostly'
p4061
aS'Dickinson were'
p4062
aS'effects predominated'
p4063
aS'relevant for virus'
p4064
aS'least one adverse'
p4065
aS'present formulation'
p4066
aS'cell responses against'
p4067
aS'reported nasal adverse'
p4068
aS'chronic carriage'
p4069
aS'monitored'
p4070
aS'consistently demonstrated'
p4071
aS'demonstrates'
p4072
aS'avoid'
p4073
aS'serum clinical'
p4074
aS'presenting cells APCs'
p4075
aS'were filled'
p4076
aS'candidate developed seroprotective'
p4077
aS'18 45'
p4078
aS'HBcAg immunomodulation'
p4079
aS'formulation and device'
p4080
aS'itching palate'
p4081
aS'head tilted backwards'
p4082
aS'bothersome discomfort'
p4083
aS'percentage anti HBc'
p4084
aS'limitations'
p4085
aS'probability of detecting'
p4086
aS'coated'
p4087
aS'used Genbank accession'
p4088
aS'length recombinant HBcAg'
p4089
aS'Center for Drug'
p4090
aS'outpatient basis'
p4091
aS'samples and reagents'
p4092
aS'6 13'
p4093
aS'adverse reaction'
p4094
aS'mucosal immunization'
p4095
aS'other developed anti'
p4096
aS'HBc UMELISA Immunoassay'
p4097
aS'stage'
p4098
aS'adults 30'
p4099
aS'fever chills'
p4100
aS'co purified'
p4101
aS'8 general'
p4102
aS'statistically significant'
p4103
aS'gene vaccine'
p4104
aS'carrier'
p4105
aS'candidate and 10'
p4106
aS'cytokine'
p4107
aS'time day'
p4108
aS'term consequences'
p4109
aS'Also chronic'
p4110
aS'neither irritating nor'
p4111
aS'HBcAg over'
p4112
aS'compromised hosts'
p4113
aS'Sera'
p4114
aS'Two'
p4115
aS'12h post'
p4116
aS'spontaneously and patients'
p4117
aS'nasal conditions occurred'
p4118
aS'device Also chronic'
p4119
aS'test for continuous'
p4120
aS'specialized'
p4121
aS'liquid Each vial'
p4122
aS'Control CECMED'
p4123
aS'immunosorbent assay anti'
p4124
aS'exposure to hepatitis'
p4125
aS'X02763'
p4126
aS'nasally parenteral'
p4127
aS'individuals renal'
p4128
aS'group and one'
p4129
aS'careful performance'
p4130
aS'first vaccine dose'
p4131
aS'Biotechnology Havana Cuba'
p4132
aS'inflammatory Th1'
p4133
aS'exposure'
p4134
aS'recruited'
p4135
aS'71 in recipients'
p4136
aS'transparent liquid Each'
p4137
aS'first hour after'
p4138
aS'range 18'
p4139
aS'interest'
p4140
aS'first dose injection'
p4141
aS'immunogenicity in populations'
p4142
aS'volunteer generating'
p4143
aS'attributed'
p4144
aS'formal hypothesis testing'
p4145
aS'HBV infected patient'
p4146
aS'immunity elicited'
p4147
aS'over nasally'
p4148
aS'Following'
p4149
aS'prevent permanent impairment'
p4150
aS'responses against HBsAg'
p4151
aS'conditions occurred during'
p4152
aS'were fatal'
p4153
aS'administered through'
p4154
aS'recipients according'
p4155
aS'evident'
p4156
aS'immune compromised'
p4157
aS'Ethics Board'
p4158
aS'among individuals'
p4159
aS'signed'
p4160
aS'protein nature'
p4161
aS'wash and saliva'
p4162
aS'carriage'
p4163
aS'sterile saline solution'
p4164
aS'reporting specific post'
p4165
aS'treatment with blood'
p4166
aS'distribution'
p4167
aS'associated with functional'
p4168
aS'formulated with 50'
p4169
aS'display'
p4170
aS'4 9 Only'
p4171
aS'block'
p4172
aS'reported to elicit'
p4173
aS'rabbits'
p4174
aS'showing induction'
p4175
aS'measure'
p4176
aS'generating'
p4177
aS'Thirty days after'
p4178
aS'dose and sera'
p4179
aS'treatment group sample'
p4180
aS'were randomized'
p4181
aS'used as placebo'
p4182
aS'hematological'
p4183
aS'nasal vaccines currently'
p4184
aS'achieved antibody levels'
p4185
aS'CIGB production'
p4186
aS'attention Serious adverse'
p4187
aS'Briefly anti HBs'
p4188
aS'detect differences between'
p4189
aS'l seroprotection'
p4190
aS'43'
p4191
aS'volunteers without'
p4192
aS'anti HBs only'
p4193
aS'subjects showing antibody'
p4194
aS'Five'
p4195
aS'helpful'
p4196
aS'normal'
p4197
aS'individuals renal dialysis'
p4198
aS'30 one'
p4199
aS'6 13 excess'
p4200
aS'formulation Phase'
p4201
aS'15 minutes'
p4202
aS'body system'
p4203
aS'field of devices'
p4204
aS'had not achieved'
p4205
aS'infection Conversely'
p4206
aS'7 days post'
p4207
aS'primary outcome'
p4208
aS'screen failures included'
p4209
aS'recognize any local'
p4210
aS'adverse effects predominated'
p4211
aS'factors'
p4212
aS'persistent'
p4213
aS'minutes apart'
p4214
aS'B surface'
p4215
aS'HBs antibody were'
p4216
aS'analysis There'
p4217
aS'volumes'
p4218
aS'one subject'
p4219
aS'nasal immunogenicity'
p4220
aS'each rate percentages'
p4221
aS'infection or immunization'
p4222
aS'T cell immune'
p4223
aS'cell immune'
p4224
aS'responsiveness'
p4225
aS'major HBV antigens'
p4226
asS'10.1016/0305-0491(75)90014-0'
p4227
(lp4228
S'Alaskan king crab'
p4229
aS'1 6 diphosphatase'
p4230
aS'000 mol wt'
p4231
aS'Alaskan king'
p4232
aS'mol wt subunits'
p4233
aS'single form'
p4234
aS'40 000'
p4235
aS'Alaskan'
p4236
aS'pI'
p4237
aS'functional differences between'
p4238
aS'subunits from both'
p4239
aS'sodium dodecyl sulfate'
p4240
aS'values of pI'
p4241
aS'halves by exposure'
p4242
aS'altered to yield'
p4243
aS'isoenzyme during thermal'
p4244
aS'two 66 000'
p4245
asS'10.1037/0003-066X.33.9.821'
p4246
(lp4247
S'psychotherapy research'
p4248
aS'psychotherapy'
p4249
aS'need to control'
p4250
aS'authors suggest'
p4251
aS'placebo'
p4252
aS'inert procedure without'
p4253
aS'control for such'
p4254
aS'ref PsycINFO Database'
p4255
aS'available therapies component'
p4256
aS'placebo effect rubric'
p4257
aS'condition being treated'
p4258
aS'without specific activity'
p4259
aS'contact and therapist'
p4260
aS'term placebo group'
p4261
aS'controls in psychotherapy'
p4262
aS'discussed 26 ref'
p4263
aS'psychotherapy placebo group'
p4264
asS'10.1016/S0188-4409(03)00069-9'
p4265
(lp4266
S'body fat pattern'
p4267
aS'low income'
p4268
aS'incidence and progression'
p4269
aS'body fat'
p4270
aS'grade 1 obesity'
p4271
aS'overweight and obesity'
p4272
aS'body mass index'
p4273
aS'progression of obesity'
p4274
aS'Mexico'
p4275
aS'first follow up'
p4276
aS'obesity'
p4277
aS'mean waist circumference'
p4278
aS'follow up phases'
p4279
aS'Mexico City'
p4280
aS'fat pattern distribution'
p4281
aS'Mexican population'
p4282
aS'99 70 44'
p4283
asS'10.1016/S0002-8223(95)00279-0'
p4284
(lp4285
S'receiving nutrition advice'
p4286
aS'prenatal care'
p4287
aS'mothers reported receiving'
p4288
aS'Live Birth File'
p4289
aS'advice by maternal'
p4290
aS'Infant Death File'
p4291
aS'breast feeding'
p4292
aS'prenatal'
p4293
aS'mothers receiving'
p4294
aS'among live births'
p4295
aS'maternal characteristics among'
p4296
aS'Table 1 Percent'
p4297
aS'n 9 639'
p4298
aS'mothers receiving nutrition'
p4299
aS'characteristics among live'
p4300
aS'weighted of mothers'
p4301
aS'1 Percent weighted'
p4302
asS'10.1016/0305-0491(74)90071-6'
p4303
(lp4304
S'tanner crab'
p4305
aS'1 6 diphosphatase'
p4306
aS'tanner crab muscle'
p4307
aS'crab muscle FDPase'
p4308
aS'tanner'
p4309
aS'temperature'
p4310
aS'tanner crab over'
p4311
aS'high approaching physiological'
p4312
aS'concentrations of AMP'
p4313
aS'increase in affinity'
p4314
aS'approaching physiological concentrations'
p4315
aS'rise in pH'
p4316
aS'sensitivity for AMP'
p4317
aS'activity of FDPase'
p4318
aS'inhibitor of activity'
p4319
aS'regulation of muscle'
p4320
aS'activity of tanner'
p4321
asS'10.1016/S0306-4565(01)00023-7'
p4322
(lp4323
S'semi supine'
p4324
aS'cutaneous blood flow'
p4325
aS'evaporative heat loss'
p4326
aS'course of mean'
p4327
aS'temperature regulation'
p4328
aS'semi supine posture'
p4329
aS'Student s paired'
p4330
aS'supine and semi'
p4331
aS'SEM Difference between'
p4332
aS'supine and supine'
p4333
aS'regulation in humans'
p4334
aS'semi'
p4335
aS'selective brain cooling'
p4336
aS'than in semi'
p4337
aS'both postural conditions'
p4338
aS'influence'
p4339
aS'than in supine'
p4340
as.